PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 7880618-1 1994 Interferon-alpha (IFN-alpha) enhances the activity of the 5-fluorouracil (5-FU) prodrug 5"-deoxy-5-fluorouridine (5"-dFUrd) in colorectal cancer cells in vitro by upregulating the enzyme pyrimidine nucleoside phosphorylase (PNPase), which is responsible for converting 5"-dFUrd to 5-FU. doxifluridine 88-112 interferon alpha Mus musculus 0-16 7880618-1 1994 Interferon-alpha (IFN-alpha) enhances the activity of the 5-fluorouracil (5-FU) prodrug 5"-deoxy-5-fluorouridine (5"-dFUrd) in colorectal cancer cells in vitro by upregulating the enzyme pyrimidine nucleoside phosphorylase (PNPase), which is responsible for converting 5"-dFUrd to 5-FU. doxifluridine 88-112 interferon alpha Mus musculus 18-27 7880618-1 1994 Interferon-alpha (IFN-alpha) enhances the activity of the 5-fluorouracil (5-FU) prodrug 5"-deoxy-5-fluorouridine (5"-dFUrd) in colorectal cancer cells in vitro by upregulating the enzyme pyrimidine nucleoside phosphorylase (PNPase), which is responsible for converting 5"-dFUrd to 5-FU. doxifluridine 114-122 polyribonucleotide nucleotidyltransferase 1 Mus musculus 224-230 7880618-1 1994 Interferon-alpha (IFN-alpha) enhances the activity of the 5-fluorouracil (5-FU) prodrug 5"-deoxy-5-fluorouridine (5"-dFUrd) in colorectal cancer cells in vitro by upregulating the enzyme pyrimidine nucleoside phosphorylase (PNPase), which is responsible for converting 5"-dFUrd to 5-FU. doxifluridine 88-112 polyribonucleotide nucleotidyltransferase 1 Mus musculus 187-222 7880618-1 1994 Interferon-alpha (IFN-alpha) enhances the activity of the 5-fluorouracil (5-FU) prodrug 5"-deoxy-5-fluorouridine (5"-dFUrd) in colorectal cancer cells in vitro by upregulating the enzyme pyrimidine nucleoside phosphorylase (PNPase), which is responsible for converting 5"-dFUrd to 5-FU. doxifluridine 269-277 interferon alpha Mus musculus 0-16 7880618-1 1994 Interferon-alpha (IFN-alpha) enhances the activity of the 5-fluorouracil (5-FU) prodrug 5"-deoxy-5-fluorouridine (5"-dFUrd) in colorectal cancer cells in vitro by upregulating the enzyme pyrimidine nucleoside phosphorylase (PNPase), which is responsible for converting 5"-dFUrd to 5-FU. doxifluridine 88-112 polyribonucleotide nucleotidyltransferase 1 Mus musculus 224-230 7880618-1 1994 Interferon-alpha (IFN-alpha) enhances the activity of the 5-fluorouracil (5-FU) prodrug 5"-deoxy-5-fluorouridine (5"-dFUrd) in colorectal cancer cells in vitro by upregulating the enzyme pyrimidine nucleoside phosphorylase (PNPase), which is responsible for converting 5"-dFUrd to 5-FU. doxifluridine 269-277 interferon alpha Mus musculus 18-27 7880618-1 1994 Interferon-alpha (IFN-alpha) enhances the activity of the 5-fluorouracil (5-FU) prodrug 5"-deoxy-5-fluorouridine (5"-dFUrd) in colorectal cancer cells in vitro by upregulating the enzyme pyrimidine nucleoside phosphorylase (PNPase), which is responsible for converting 5"-dFUrd to 5-FU. doxifluridine 114-122 interferon alpha Mus musculus 0-16 7880618-8 1994 Combination treatment with 75 mg/kg/day or 150 mg/kg/day of 5"-dFUrd resulted in enhanced antitumour activity, particularly at the higher dose of IFN-alpha A/D. doxifluridine 60-68 interferon alpha Mus musculus 146-155 7880618-1 1994 Interferon-alpha (IFN-alpha) enhances the activity of the 5-fluorouracil (5-FU) prodrug 5"-deoxy-5-fluorouridine (5"-dFUrd) in colorectal cancer cells in vitro by upregulating the enzyme pyrimidine nucleoside phosphorylase (PNPase), which is responsible for converting 5"-dFUrd to 5-FU. doxifluridine 114-122 interferon alpha Mus musculus 18-27 7880618-1 1994 Interferon-alpha (IFN-alpha) enhances the activity of the 5-fluorouracil (5-FU) prodrug 5"-deoxy-5-fluorouridine (5"-dFUrd) in colorectal cancer cells in vitro by upregulating the enzyme pyrimidine nucleoside phosphorylase (PNPase), which is responsible for converting 5"-dFUrd to 5-FU. doxifluridine 114-122 polyribonucleotide nucleotidyltransferase 1 Mus musculus 187-222 7906263-0 1994 5"-Deoxy-5-fluorouridine increases daunorubicin uptake in multidrug-resistant cells and its activity is related with P-gp 170 expression. doxifluridine 0-24 phosphoglycolate phosphatase Homo sapiens 117-121 7906263-5 1994 In the present study, the cytotoxic activity of dFUrd in vitro and dFUrd combined with daunorubicin (DNR) was assessed with the (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium) bromide assay in cells with increased P-gp 170 expression versus controls. doxifluridine 48-53 phosphoglycolate phosphatase Homo sapiens 221-225 7906263-6 1994 Surprisingly, dFUrd was most active in cells with high P-gp 170 expression, a finding which can not be explained by intracellular metabolic activity only. doxifluridine 14-19 phosphoglycolate phosphatase Homo sapiens 55-59 8249177-13 1993 CONCLUSIONS: The maximum tolerated dose of oral doxifluridine in combination with standard radiotherpay was assessed at 1000 mg/patient/day (equivalent to 36-38 g monthly, previously reported as mTD in phase I studies). doxifluridine 48-61 BCL2-related ovarian killer Mus musculus 195-198 8116077-3 1993 In general, the maximum monthly dose of 5"-dFUR was 36-38 g. According to these clinical data, we explored the feasibility of a combination of 5"-dFUR and interferon-alpha-2a (IFN-alpha-2a). doxifluridine 40-47 interferon alpha 2 Homo sapiens 155-174 8102068-11 1993 The sensitivity of KB cells transfected with PD-ECGF cDNA to doxifluridine was considerably higher than that of non-transfected KB cells. doxifluridine 61-74 thymidine phosphorylase Homo sapiens 45-52 8486533-2 1993 Tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon gamma (IFN gamma) at low doses showing < 50% inhibition of cell growth by themselves enhanced the susceptibility of the cells to the activity of 5"-dFUrd. doxifluridine 238-246 tumor necrosis factor Mus musculus 0-27 8486533-2 1993 Tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon gamma (IFN gamma) at low doses showing < 50% inhibition of cell growth by themselves enhanced the susceptibility of the cells to the activity of 5"-dFUrd. doxifluridine 238-246 tumor necrosis factor Mus musculus 29-38 8486533-2 1993 Tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon gamma (IFN gamma) at low doses showing < 50% inhibition of cell growth by themselves enhanced the susceptibility of the cells to the activity of 5"-dFUrd. doxifluridine 238-246 interferon gamma Mus musculus 79-95 8486533-2 1993 Tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon gamma (IFN gamma) at low doses showing < 50% inhibition of cell growth by themselves enhanced the susceptibility of the cells to the activity of 5"-dFUrd. doxifluridine 238-246 interferon gamma Mus musculus 97-106 8486533-7 1993 Consequently, the anabolism of 5"-dFUrd to fluoronucleotides and the incorporation of 5-FUra into RNA in colon 26 cells were increased by TNF alpha treatment. doxifluridine 31-39 tumor necrosis factor Mus musculus 138-147 8339382-1 1993 The present study shows that various cytokines such as tumor necrosis factor (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon-gamma (IFN gamma) make tumor cells much more susceptible to the cytostatic 5"-deoxy-5-fluorouridine (5"-dFUrd) than to 5-fluorouracil (5-FUra) and other cytostatics. doxifluridine 214-238 interleukin 1 alpha Homo sapiens 90-109 8339382-1 1993 The present study shows that various cytokines such as tumor necrosis factor (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon-gamma (IFN gamma) make tumor cells much more susceptible to the cytostatic 5"-deoxy-5-fluorouridine (5"-dFUrd) than to 5-fluorouracil (5-FUra) and other cytostatics. doxifluridine 214-238 interleukin 1 alpha Homo sapiens 111-121 8339382-1 1993 The present study shows that various cytokines such as tumor necrosis factor (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon-gamma (IFN gamma) make tumor cells much more susceptible to the cytostatic 5"-deoxy-5-fluorouridine (5"-dFUrd) than to 5-fluorouracil (5-FUra) and other cytostatics. doxifluridine 214-238 interferon gamma Homo sapiens 128-144 8339382-1 1993 The present study shows that various cytokines such as tumor necrosis factor (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon-gamma (IFN gamma) make tumor cells much more susceptible to the cytostatic 5"-deoxy-5-fluorouridine (5"-dFUrd) than to 5-fluorouracil (5-FUra) and other cytostatics. doxifluridine 214-238 interferon gamma Homo sapiens 146-155 8339382-1 1993 The present study shows that various cytokines such as tumor necrosis factor (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon-gamma (IFN gamma) make tumor cells much more susceptible to the cytostatic 5"-deoxy-5-fluorouridine (5"-dFUrd) than to 5-fluorouracil (5-FUra) and other cytostatics. doxifluridine 240-248 interleukin 1 alpha Homo sapiens 90-109 8339382-1 1993 The present study shows that various cytokines such as tumor necrosis factor (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon-gamma (IFN gamma) make tumor cells much more susceptible to the cytostatic 5"-deoxy-5-fluorouridine (5"-dFUrd) than to 5-fluorouracil (5-FUra) and other cytostatics. doxifluridine 240-248 interleukin 1 alpha Homo sapiens 111-121 8339382-1 1993 The present study shows that various cytokines such as tumor necrosis factor (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon-gamma (IFN gamma) make tumor cells much more susceptible to the cytostatic 5"-deoxy-5-fluorouridine (5"-dFUrd) than to 5-fluorouracil (5-FUra) and other cytostatics. doxifluridine 240-248 interferon gamma Homo sapiens 128-144 8339382-1 1993 The present study shows that various cytokines such as tumor necrosis factor (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon-gamma (IFN gamma) make tumor cells much more susceptible to the cytostatic 5"-deoxy-5-fluorouridine (5"-dFUrd) than to 5-fluorouracil (5-FUra) and other cytostatics. doxifluridine 240-248 interferon gamma Homo sapiens 146-155 8339382-4 1993 The increased susceptibility would be a result of the induction of thymidine phosphorylase (TdR Pase), which is the essential enzyme for the conversion of 5"-dFUrd to 5-FUra. doxifluridine 155-163 thymidine phosphorylase Homo sapiens 92-100 34847429-2 2022 The shielding group (5"-DFUR) was found to be effective in prolonging circulation at physiological pH 7.4 and improving accumulation in the acidic microenvironment of the tumor. doxifluridine 21-28 phenylalanine hydroxylase Homo sapiens 99-101 14701834-1 2004 We previously reported that the human Na(+)/nucleoside transporter pyrimidine-preferring 1 (hCNT1) is electrogenic and transports gemcitabine and 5"-deoxy-5-fluorouridine, a precursor of the active drug 5-fluorouracil. doxifluridine 146-170 solute carrier family 28 member 1 Homo sapiens 92-97 1534247-0 1992 Interactions of interferon-alpha 2a with 5"-deoxy-5-fluorouridine in colorectal cancer cells in vitro. doxifluridine 41-65 interferon alpha 2 Homo sapiens 16-35 1534247-4 1992 In contrast, interactive enhancement of IFN-alpha was observed with 5"-dFUrd in five lines (WiDr, HT-29, 513, SW-480 and Co-115). doxifluridine 68-76 interferon alpha 2 Homo sapiens 40-49 1824924-0 1991 Activation and cytotoxicity of 5"-deoxy-5-fluorouridine in c-H-ras transformed NIH 3T3 cells. doxifluridine 31-55 Harvey rat sarcoma virus oncogene Mus musculus 59-66 1824924-1 1991 Transformation of NIH 3T3 cells with c-H-ras has been demonstrated to result in significantly increased activation of 5"-deoxy-5-fluorouridine and significantly increased cytotoxicity in vitro as compared to non-transformed NIH 3T3. doxifluridine 118-142 Harvey rat sarcoma virus oncogene Mus musculus 37-44 3395138-1 1988 We investigated the relationships between antitumor activity and the inhibition of Thymidylate Synthase (TS) activity after oral administration of 5-fluorouracil (FUra) and its derivatives, FT, UFT, HC-FU, PH-FU and 5"-DFUR, using mainly Sarcoma 180 as an experimental tumor model. doxifluridine 216-223 thymidylate synthase Mus musculus 105-107 3161854-1 1985 5"-Deoxy-5-fluorouridine (5"-DFUR) was evaluated for antitumor activity against four murine tumors (L1210 leukemia, P388 leukemia, Lewis lung carcinoma, and B16 melanoma) and a human mammary carcinoma (MX-1) xenografted in athymic mice. doxifluridine 0-24 MX dynamin like GTPase 1 Homo sapiens 202-206 2947416-0 1986 Passage of 5"-dFUrd and its metabolites 5-FU and 5-FUH2 to CSF in a clinical phase 1 study. doxifluridine 11-19 colony stimulating factor 2 Homo sapiens 59-62 2947416-2 1986 5"-dFUrd, 5"FU, and 5-FUH2 were shown to cross the blood-brain barrier to CSF. doxifluridine 0-8 colony stimulating factor 2 Homo sapiens 74-77 2969304-1 1988 Uridine (UR) inhibits the metabolic activation of 5"-deoxy-5-fluorouridine (dFUR) to 5-fluorouracil (FU) by the intestinal pyrimidine nucleoside phosphorylases and could potentially reduce its intestinal toxicity. doxifluridine 50-74 fur Drosophila melanogaster 76-80 2972339-0 1988 Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat. doxifluridine 59-72 thymidylate synthetase Rattus norvegicus 14-34 2977647-1 1987 The activity of 5"-deoxy-5-fluorouridine (dFUR) depends on its activation to 5-fluorouracil (FU) by pyrimidine nucleoside phosphorylases. doxifluridine 16-40 fur Drosophila melanogaster 42-46 2947416-4 1986 5-FUH2 showed a marked increase in CSF between 3 and 4 h to about 40-60% of the maximal plasma concentration in 5 of the patients, indicating a possible further increase after 4 h. The relationship between the concentrations of 5"-dFUrd and its metabolites in the CSF, and CNS toxicity is discussed. doxifluridine 228-236 colony stimulating factor 2 Homo sapiens 35-38 3161854-3 1985 5"-DFUR showed a marked antitumor activity against MX-1 implanted subcutaneously and also showed slight antitumor activity against Lewis lung carcinoma implanted subcutaneously, while 5-FU and FT-207 did not show any significant antitumor activity against these tumors. doxifluridine 0-7 MX dynamin-like GTPase 1 Mus musculus 51-55 32559325-6 2021 RESULTS: The PK model incorporates oxaliplatin as a covariate on absorption lag time, rs6720173 (ABCG5 gene) on clearance of 5"-DFUR (182% increase for mutated rs6720173) and rs2271862 (ABCA2 gene) on clearance of 5-FU (184% increase for mutated rs2271862). doxifluridine 125-132 ATP binding cassette subfamily G member 5 Homo sapiens 97-102 32559325-6 2021 RESULTS: The PK model incorporates oxaliplatin as a covariate on absorption lag time, rs6720173 (ABCG5 gene) on clearance of 5"-DFUR (182% increase for mutated rs6720173) and rs2271862 (ABCA2 gene) on clearance of 5-FU (184% increase for mutated rs2271862). doxifluridine 125-132 ATP binding cassette subfamily A member 2 Homo sapiens 186-191 25596051-11 2014 The CBR was significantly higher for patients with no visceral metastasis (p=0.032), TS-1 used as third-line treatment or earlier (p=0.019), negative HER2 status (p= 0.045), no history of CAP therapy (p=0.006), and no history of tegafur-uracil/doxifluridine therapy (p=0.031). doxifluridine 244-257 cannabinoid receptor 1 Homo sapiens 4-7 33007506-0 2021 Doxifluridine-based pharmacosomes delivering miR-122 as tumor microenvironments-activated nanoplatforms for synergistic treatment of hepatocellular carcinoma. doxifluridine 0-13 microRNA 122 Homo sapiens 45-52 33144465-2 2020 This prospective pharmacokinetic study evaluated cytidine deaminase (CDA) activity, the second drug-metabolizing enzyme that generates 5"-deoxy-5-fluorouridine (5"-DFUR) from 5"-deoxy-5-fluorocytidine (5"-DFCR), as well as creatinine clearance (CLcr). doxifluridine 135-159 cytidine deaminase Homo sapiens 49-67 33144465-2 2020 This prospective pharmacokinetic study evaluated cytidine deaminase (CDA) activity, the second drug-metabolizing enzyme that generates 5"-deoxy-5-fluorouridine (5"-DFUR) from 5"-deoxy-5-fluorocytidine (5"-DFCR), as well as creatinine clearance (CLcr). doxifluridine 135-159 cytidine deaminase Homo sapiens 69-72 33144465-2 2020 This prospective pharmacokinetic study evaluated cytidine deaminase (CDA) activity, the second drug-metabolizing enzyme that generates 5"-deoxy-5-fluorouridine (5"-DFUR) from 5"-deoxy-5-fluorocytidine (5"-DFCR), as well as creatinine clearance (CLcr). doxifluridine 161-168 cytidine deaminase Homo sapiens 49-67 33144465-2 2020 This prospective pharmacokinetic study evaluated cytidine deaminase (CDA) activity, the second drug-metabolizing enzyme that generates 5"-deoxy-5-fluorouridine (5"-DFUR) from 5"-deoxy-5-fluorocytidine (5"-DFCR), as well as creatinine clearance (CLcr). doxifluridine 161-168 cytidine deaminase Homo sapiens 69-72 27364610-0 2016 Doxifluridine-conjugated 2-5A analog shows strong RNase L activation ability and tumor suppressive effect. doxifluridine 0-13 ribonuclease L Homo sapiens 50-57 27364610-4 2016 The doxifluridine-conjugated 8-methyladenosine-substituted 2-5A analog was significantly more effective as an activator of RNase L than the parent 5"-monophophorylated 2-5A tetramer and showed a tumor suppressive effect against human cervical cancer cells. doxifluridine 4-17 ribonuclease L Homo sapiens 123-130 32458030-10 2020 Higher CES1 activity expressed as a metabolic ratio (AUC of capecitabine/sum of three AUCs of each metabolite) lower than its mean was associated with higher 5"-DFUR AUC/dose and lower RDI, indicating essential roles of CES1 in capecitabine activation to produce 5"-DFUR. doxifluridine 158-165 carboxylesterase 1 Homo sapiens 7-11 32458030-10 2020 Higher CES1 activity expressed as a metabolic ratio (AUC of capecitabine/sum of three AUCs of each metabolite) lower than its mean was associated with higher 5"-DFUR AUC/dose and lower RDI, indicating essential roles of CES1 in capecitabine activation to produce 5"-DFUR. doxifluridine 158-165 carboxylesterase 1 Homo sapiens 220-224 32458030-10 2020 Higher CES1 activity expressed as a metabolic ratio (AUC of capecitabine/sum of three AUCs of each metabolite) lower than its mean was associated with higher 5"-DFUR AUC/dose and lower RDI, indicating essential roles of CES1 in capecitabine activation to produce 5"-DFUR. doxifluridine 263-270 carboxylesterase 1 Homo sapiens 7-11 32066801-1 2020 Capecitabine is selectively converted from 5"-DFUR to 5-fluorouracil (5-FU) in tumours by thymidine phosphorylase (TP). doxifluridine 43-50 thymidine phosphorylase Homo sapiens 90-113 32066801-1 2020 Capecitabine is selectively converted from 5"-DFUR to 5-fluorouracil (5-FU) in tumours by thymidine phosphorylase (TP). doxifluridine 43-50 thymidine phosphorylase Homo sapiens 115-117 29212503-5 2017 RESULTS: Combined treatment with equipotent doses of VPA and 5"-DFUR resulted in synergistic effects in CRC lines expressing p53 (wild-type or mutant). doxifluridine 61-68 tumor protein p53 Homo sapiens 125-128 25877313-0 2015 [Transfection of thymidine phosphorylase cDNA with lentiviral vector enhances the anticancer effect of 5"-deoxy-5-fluorouridine on colorectal cancer cell lines HT29 and LS174T]. doxifluridine 103-127 thymidine phosphorylase Homo sapiens 17-40 25877313-1 2015 OBJECTIVE: To explore the changes of anticancer efficiency of 5"-deoxy-5-fluorouridine (5"-DFUR) and 5-fluorouracil (5-Fu) in colorectal cancer cell line HT29 and LS174T cells after transfection of thymidine phosphorylase (TP) cDNA with a lentiviral vector. doxifluridine 62-86 thymidine phosphorylase Homo sapiens 198-221 25877313-1 2015 OBJECTIVE: To explore the changes of anticancer efficiency of 5"-deoxy-5-fluorouridine (5"-DFUR) and 5-fluorouracil (5-Fu) in colorectal cancer cell line HT29 and LS174T cells after transfection of thymidine phosphorylase (TP) cDNA with a lentiviral vector. doxifluridine 62-86 thymidine phosphorylase Homo sapiens 223-225 25877313-1 2015 OBJECTIVE: To explore the changes of anticancer efficiency of 5"-deoxy-5-fluorouridine (5"-DFUR) and 5-fluorouracil (5-Fu) in colorectal cancer cell line HT29 and LS174T cells after transfection of thymidine phosphorylase (TP) cDNA with a lentiviral vector. doxifluridine 88-95 thymidine phosphorylase Homo sapiens 198-221 25877313-1 2015 OBJECTIVE: To explore the changes of anticancer efficiency of 5"-deoxy-5-fluorouridine (5"-DFUR) and 5-fluorouracil (5-Fu) in colorectal cancer cell line HT29 and LS174T cells after transfection of thymidine phosphorylase (TP) cDNA with a lentiviral vector. doxifluridine 88-95 thymidine phosphorylase Homo sapiens 223-225 25877313-10 2015 The IC50 values of 5"-DFUR on HT29-TP cells and its parents cell were (14.33 +- 0.74) micromol/L and (707.66 +- 5.66) micromol/L, respectively (P < 0.05), while (0.59 +- 0.11) micromol/L in LS174T-TP cells and (239.20 +- 21.83) micromol/L in its parent cells, respectively (P < 0.05). doxifluridine 19-26 thymidine phosphorylase Homo sapiens 35-37 25877313-10 2015 The IC50 values of 5"-DFUR on HT29-TP cells and its parents cell were (14.33 +- 0.74) micromol/L and (707.66 +- 5.66) micromol/L, respectively (P < 0.05), while (0.59 +- 0.11) micromol/L in LS174T-TP cells and (239.20 +- 21.83) micromol/L in its parent cells, respectively (P < 0.05). doxifluridine 19-26 thymidine phosphorylase Homo sapiens 200-202 25877313-12 2015 The HPLC results showed that the 5-Fu concentration detected from media contained a series of concentrations of 5"-DFUR for culturing HT29-TP and LS174T-TP cells were 12.2 to 28.7-folds and 13.1 to 23.6-folds, respectively, higher than that in their parents cells, (P < 0.01 for all). doxifluridine 112-119 thymidine phosphorylase Homo sapiens 139-141 25877313-12 2015 The HPLC results showed that the 5-Fu concentration detected from media contained a series of concentrations of 5"-DFUR for culturing HT29-TP and LS174T-TP cells were 12.2 to 28.7-folds and 13.1 to 23.6-folds, respectively, higher than that in their parents cells, (P < 0.01 for all). doxifluridine 112-119 thymidine phosphorylase Homo sapiens 153-155 25877313-14 2015 CONCLUSIONS: Transfection of TP cDNA into colorectal cancer cell lines HT29 and LS174T with lentiviral vector can improve the expression of both TP mRNA and TP protein levels in passaged cells, enhance the conversion of 5-Fu from 5"-DFUR in the medium, and result in an enhanced anticancer effect on these two cell lines. doxifluridine 230-237 thymidine phosphorylase Homo sapiens 29-31 25877313-14 2015 CONCLUSIONS: Transfection of TP cDNA into colorectal cancer cell lines HT29 and LS174T with lentiviral vector can improve the expression of both TP mRNA and TP protein levels in passaged cells, enhance the conversion of 5-Fu from 5"-DFUR in the medium, and result in an enhanced anticancer effect on these two cell lines. doxifluridine 230-237 thymidine phosphorylase Homo sapiens 145-147 25877313-14 2015 CONCLUSIONS: Transfection of TP cDNA into colorectal cancer cell lines HT29 and LS174T with lentiviral vector can improve the expression of both TP mRNA and TP protein levels in passaged cells, enhance the conversion of 5-Fu from 5"-DFUR in the medium, and result in an enhanced anticancer effect on these two cell lines. doxifluridine 230-237 thymidine phosphorylase Homo sapiens 145-147 25448717-0 2014 Interaction of 5-fluoro-5"-deoxyuridine with human serum albumin under physiological and non-physiological condition: a biophysical investigation. doxifluridine 15-39 albumin Homo sapiens 51-64 23898114-0 2013 UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5"-deoxy-5-fluorouridine (5"-DFUR) for metastatic colorectal cancer. doxifluridine 97-121 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 0-37 24219283-6 2013 Treatment of RCC cell lines with interferon alpha (IFN-alpha) increased thymidine phosphorylase levels and prior treatment of RCC cell lines with IFN-alpha followed by 5-FU or DFUR resulted in enhanced sensitivity of all cell lines to 5-FU and two of three cell lines to DFUR. doxifluridine 176-180 interferon alpha 1 Homo sapiens 33-60 24219283-6 2013 Treatment of RCC cell lines with interferon alpha (IFN-alpha) increased thymidine phosphorylase levels and prior treatment of RCC cell lines with IFN-alpha followed by 5-FU or DFUR resulted in enhanced sensitivity of all cell lines to 5-FU and two of three cell lines to DFUR. doxifluridine 176-180 interferon alpha 1 Homo sapiens 51-60 24219283-6 2013 Treatment of RCC cell lines with interferon alpha (IFN-alpha) increased thymidine phosphorylase levels and prior treatment of RCC cell lines with IFN-alpha followed by 5-FU or DFUR resulted in enhanced sensitivity of all cell lines to 5-FU and two of three cell lines to DFUR. doxifluridine 271-275 interferon alpha 1 Homo sapiens 33-60 24219283-6 2013 Treatment of RCC cell lines with interferon alpha (IFN-alpha) increased thymidine phosphorylase levels and prior treatment of RCC cell lines with IFN-alpha followed by 5-FU or DFUR resulted in enhanced sensitivity of all cell lines to 5-FU and two of three cell lines to DFUR. doxifluridine 271-275 interferon alpha 1 Homo sapiens 51-60 24100378-6 2013 In the presence of PBMCs, PSK augmented the inhibitory effects of 5-FU and 5"-DFUR on HCT116 cell proliferation. doxifluridine 75-82 TAO kinase 2 Homo sapiens 26-29 24100378-11 2013 The present results propose the possibility that PSK induces PBMCs to express IFN-alpha which inhibits DPD expression, and consequently augments the antitumor effect of 5-FU or 5"-DFUR. doxifluridine 177-184 TAO kinase 2 Homo sapiens 49-52 24100378-11 2013 The present results propose the possibility that PSK induces PBMCs to express IFN-alpha which inhibits DPD expression, and consequently augments the antitumor effect of 5-FU or 5"-DFUR. doxifluridine 177-184 interferon alpha 1 Homo sapiens 78-87 24022189-8 2013 Elevation of DFUR Cmax (45%) and AUC (46%) (P<0.05) was also noted, suggesting that CDA activity may be higher in females. doxifluridine 13-17 cytidine deaminase Homo sapiens 87-90 23898114-0 2013 UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5"-deoxy-5-fluorouridine (5"-DFUR) for metastatic colorectal cancer. doxifluridine 123-130 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 0-37 23898114-1 2013 AIM: We performed a phase II study of irinotecan with 5"-deoxy-5-fluorouridine (5"-DFUR) for metastatic colorectal cancer based on UDP-glucuronosyltransferase (UGT) 1A1 polymorphism. doxifluridine 54-78 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 131-168 23898114-1 2013 AIM: We performed a phase II study of irinotecan with 5"-deoxy-5-fluorouridine (5"-DFUR) for metastatic colorectal cancer based on UDP-glucuronosyltransferase (UGT) 1A1 polymorphism. doxifluridine 80-87 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 131-168 23229803-7 2013 The antitumor activity of capecitabine and 5"-DFUR correlated significantly with the mRNA levels of TP and with the TP/DPD ratio, whereas the activity of 5-FU correlated significantly with OPRT, TMPK, UMPK and CD. doxifluridine 43-50 dihydropyrimidine dehydrogenase Homo sapiens 131-134 23608802-0 2013 [Effect of thymidine phosphorylase cDNA transfection on the inhibition of human colon carcinoma cell line by 5"-deoxy-5-fluorouridine]. doxifluridine 109-133 thymidine phosphorylase Homo sapiens 11-34 23608802-1 2013 OBJECTIVE: To investigate the inhibiting impact of 5"-deoxy-5-fluorouridine (5"-DFUR) on human colon carcinoma cell line LOVO after transfection of thymidine phosphorylase (TP) cDNA. doxifluridine 51-75 thymidine phosphorylase Homo sapiens 148-171 23608802-1 2013 OBJECTIVE: To investigate the inhibiting impact of 5"-deoxy-5-fluorouridine (5"-DFUR) on human colon carcinoma cell line LOVO after transfection of thymidine phosphorylase (TP) cDNA. doxifluridine 51-75 thymidine phosphorylase Homo sapiens 173-175 23608802-1 2013 OBJECTIVE: To investigate the inhibiting impact of 5"-deoxy-5-fluorouridine (5"-DFUR) on human colon carcinoma cell line LOVO after transfection of thymidine phosphorylase (TP) cDNA. doxifluridine 77-84 thymidine phosphorylase Homo sapiens 148-171 23608802-1 2013 OBJECTIVE: To investigate the inhibiting impact of 5"-deoxy-5-fluorouridine (5"-DFUR) on human colon carcinoma cell line LOVO after transfection of thymidine phosphorylase (TP) cDNA. doxifluridine 77-84 thymidine phosphorylase Homo sapiens 173-175 23608802-4 2013 The IC50 of 5"-DFUR on TP-transfected LOVO and parental cell were evaluated by MTT assay. doxifluridine 12-19 thymidine phosphorylase Homo sapiens 23-25 23608802-8 2013 The IC50 value of 5"-DFUR of TP-transfectants was (1087.7+-89.1) mumol/L, less than (1607.3+-56.8) mumol/L of parental cells significantly (P<0.01), while there was no significant difference between parental cells and vector-transfectants [(1699.5+-38.7) mumol/L, P>0.05]. doxifluridine 18-25 thymidine phosphorylase Homo sapiens 29-31 23608802-9 2013 HPLC revealed that when medium was added with 0, 500, 1000, and 2000 mumol/L of 5"-DFUR respectively, 0, 2.10, 3.13, and 7.19 mumol/L of 5-FU was found in the parental cells culture, while 0, 22.16, 30.94 and 40.02 mumol/L of 5-FU was found in TP-transfectants culture, but no 5-FU was found in the vector-transfectants culture. doxifluridine 80-87 thymidine phosphorylase Homo sapiens 244-246 23608802-10 2013 CONCLUSION: TP cDNA transfection into LOVO can up-regulate the TP mRNA and protein expressions, increase the 5-FU converted from 5"-DFUR, and enhance the cytotoxic effect of 5"-DFUR on the LOVO cells. doxifluridine 129-136 thymidine phosphorylase Homo sapiens 12-14 23608802-10 2013 CONCLUSION: TP cDNA transfection into LOVO can up-regulate the TP mRNA and protein expressions, increase the 5-FU converted from 5"-DFUR, and enhance the cytotoxic effect of 5"-DFUR on the LOVO cells. doxifluridine 174-181 thymidine phosphorylase Homo sapiens 12-14 23229803-8 2013 In a stepwise regression analysis, TP and DPD were found to be independent predictive factors of sensitivity to capecitabine and 5"-DFUR, and UMPK was predictive of sensitivity to 5-FU. doxifluridine 153-160 dihydropyrimidine dehydrogenase Homo sapiens 54-57 24027750-0 2013 Interferon-alpha enhances 5"-deoxy-5-fluorouridine-induced apoptosis by ERK-dependant upregulation of thymidine phosphorylase. doxifluridine 26-50 mitogen-activated protein kinase 1 Homo sapiens 72-75 23017148-9 2012 CONCLUSIONS: Based on the results, we propose that the aquaglyceroporin AQP3 is required for cytotoxic activity of 5"-DFUR and gemcitabine in the breast cancer cell line MCF7 and the colon adenocarcinoma cell line HT29, and is implicated in cell volume increase and cell cycle arrest. doxifluridine 115-122 aquaporin 3 (Gill blood group) Homo sapiens 72-76 23017148-1 2012 BACKGROUND: Nucleoside analogs used in the chemotherapy of solid tumors, such as the capecitabine catabolite 5"-deoxy-5-fluorouridine (5"-DFUR) trigger a transcriptomic response that involves the aquaglyceroporin aquaporin 3 along with other p53-dependent genes. doxifluridine 109-133 aquaporin 3 (Gill blood group) Homo sapiens 213-224 20953739-9 2011 In a univariate analysis, the doxifluridine-treated patients with MSI-H showed improved RFS compared to those with low or stable MSI (MSI-L/S) (P = 0.036), while the MSI status was not significantly associated with OS (P = 0.107). doxifluridine 30-43 RB binding protein 4, chromatin remodeling factor Homo sapiens 66-69 23017148-1 2012 BACKGROUND: Nucleoside analogs used in the chemotherapy of solid tumors, such as the capecitabine catabolite 5"-deoxy-5-fluorouridine (5"-DFUR) trigger a transcriptomic response that involves the aquaglyceroporin aquaporin 3 along with other p53-dependent genes. doxifluridine 109-133 tumor protein p53 Homo sapiens 242-245 23017148-1 2012 BACKGROUND: Nucleoside analogs used in the chemotherapy of solid tumors, such as the capecitabine catabolite 5"-deoxy-5-fluorouridine (5"-DFUR) trigger a transcriptomic response that involves the aquaglyceroporin aquaporin 3 along with other p53-dependent genes. doxifluridine 135-142 aquaporin 3 (Gill blood group) Homo sapiens 213-224 23017148-1 2012 BACKGROUND: Nucleoside analogs used in the chemotherapy of solid tumors, such as the capecitabine catabolite 5"-deoxy-5-fluorouridine (5"-DFUR) trigger a transcriptomic response that involves the aquaglyceroporin aquaporin 3 along with other p53-dependent genes. doxifluridine 135-142 tumor protein p53 Homo sapiens 242-245 23017148-2 2012 Here, we examined whether up-regulation of aquaporin 3 (AQP3) mRNA in cancer cells treated with 5"-DFUR represents a collateral transcriptomic effect of the drug, or conversely, AQP3 participates in the activity of genotoxic agents. doxifluridine 96-103 aquaporin 3 (Gill blood group) Homo sapiens 43-54 23017148-2 2012 Here, we examined whether up-regulation of aquaporin 3 (AQP3) mRNA in cancer cells treated with 5"-DFUR represents a collateral transcriptomic effect of the drug, or conversely, AQP3 participates in the activity of genotoxic agents. doxifluridine 96-103 aquaporin 3 (Gill blood group) Homo sapiens 56-60 23017148-4 2012 RESULTS: 5"-DFUR and gemcitabine, but not cisplatin, stimulated AQP3 expression and cell volume, which was partially and significantly blocked by knockdown of AQP3. doxifluridine 9-16 aquaporin 3 (Gill blood group) Homo sapiens 64-68 23017148-4 2012 RESULTS: 5"-DFUR and gemcitabine, but not cisplatin, stimulated AQP3 expression and cell volume, which was partially and significantly blocked by knockdown of AQP3. doxifluridine 9-16 aquaporin 3 (Gill blood group) Homo sapiens 159-163 22480411-10 2012 CONCLUSIONS: These results suggest a clinical advantage of chemoradiotherapy with capecitabine or doxyfluridine over radiotherapy alone via the elevation of the TP/DPD ratio in cervical squamous cell carcinoma. doxifluridine 98-111 dihydropyrimidine dehydrogenase Homo sapiens 164-167 20953739-9 2011 In a univariate analysis, the doxifluridine-treated patients with MSI-H showed improved RFS compared to those with low or stable MSI (MSI-L/S) (P = 0.036), while the MSI status was not significantly associated with OS (P = 0.107). doxifluridine 30-43 RB binding protein 4, chromatin remodeling factor Homo sapiens 134-141 20953739-9 2011 In a univariate analysis, the doxifluridine-treated patients with MSI-H showed improved RFS compared to those with low or stable MSI (MSI-L/S) (P = 0.036), while the MSI status was not significantly associated with OS (P = 0.107). doxifluridine 30-43 RB binding protein 4, chromatin remodeling factor Homo sapiens 129-132 21830159-0 2011 Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer. doxifluridine 45-58 proteasome 26S subunit, non-ATPase 1 Homo sapiens 76-79 19602572-7 2009 Finally, the overexpression of PGC-1alpha sensitizes breast and colon cancer cells to growth inhibition by 5"-DFUR presumably by inducing apoptosis in tumor cells and XCT790 can inhibit the process. doxifluridine 107-114 PPARG coactivator 1 alpha Homo sapiens 31-41 21631643-7 2011 Doxifluridine suppressed tube formation of HUVEC and vascular endothelial growth factor production by FU-MMT-1 cells. doxifluridine 0-13 vascular endothelial growth factor A Homo sapiens 53-87 21756828-10 2011 The sensitivity to doxifluridine and capecitabine in AGS-pTP was significantly increased, as compared with that in AGS-p. IC50 values of AGS-pTP to doxifluridine and capecitabine were estimated 1.7 folds and 2.2 folds as much as that of AGS-p, respectively. doxifluridine 19-32 protein tyrosine phosphatase receptor type U Homo sapiens 57-60 21756828-10 2011 The sensitivity to doxifluridine and capecitabine in AGS-pTP was significantly increased, as compared with that in AGS-p. IC50 values of AGS-pTP to doxifluridine and capecitabine were estimated 1.7 folds and 2.2 folds as much as that of AGS-p, respectively. doxifluridine 19-32 protein tyrosine phosphatase receptor type U Homo sapiens 141-144 21756828-10 2011 The sensitivity to doxifluridine and capecitabine in AGS-pTP was significantly increased, as compared with that in AGS-p. IC50 values of AGS-pTP to doxifluridine and capecitabine were estimated 1.7 folds and 2.2 folds as much as that of AGS-p, respectively. doxifluridine 148-161 protein tyrosine phosphatase receptor type U Homo sapiens 57-60 21756828-10 2011 The sensitivity to doxifluridine and capecitabine in AGS-pTP was significantly increased, as compared with that in AGS-p. IC50 values of AGS-pTP to doxifluridine and capecitabine were estimated 1.7 folds and 2.2 folds as much as that of AGS-p, respectively. doxifluridine 148-161 protein tyrosine phosphatase receptor type U Homo sapiens 141-144 21756828-12 2011 CONCLUSIONS: Enhancement of TP expression improves the sensitivity of gastric carcinoma cells to doxifluridine and capecitabine. doxifluridine 97-110 thymidine phosphorylase Homo sapiens 28-30 21876743-13 2011 Kaplan-Meier survival analysis revealed that low levels of miR-21 expression (Log rank test, hazard ratio: 0.17, CI = 0.06-0.45; P = 0.0004) and miR-181b (Log rank test, hazard ratio: 0.37, CI = 0.16-0.87; P = 0.018) are closely associated with better patient"s overall survival for both S-1 and Doxifluridine based regimens. doxifluridine 296-309 microRNA 21 Homo sapiens 59-65 22966291-3 2010 We focused on thymidine phosphorylase (TP), an enzyme metabolizing 5"-DFUR, an intermediate of capecitabine, to 5-fluorouracil in order to investigate the application of well-known therapeutics for TNBC. doxifluridine 67-74 thymidine phosphorylase Homo sapiens 14-37 22966291-3 2010 We focused on thymidine phosphorylase (TP), an enzyme metabolizing 5"-DFUR, an intermediate of capecitabine, to 5-fluorouracil in order to investigate the application of well-known therapeutics for TNBC. doxifluridine 67-74 thymidine phosphorylase Homo sapiens 39-41 19602572-0 2009 Peroxisome proliferator-activated receptor gamma coactivator-1alpha enhances antiproliferative activity of 5"-deoxy-5-fluorouridine in cancer cells through induction of uridine phosphorylase. doxifluridine 107-131 PPARG coactivator 1 alpha Homo sapiens 0-67 19602572-3 2009 This study demonstrates uridine phosphorylase as a novel target gene of PGC-1alpha, which induces the transcription and enzymatic activity of UPase in various cancer cells and thus augments their susceptibility to 5"-DFUR. doxifluridine 214-221 PPARG coactivator 1 alpha Homo sapiens 72-82 20214978-8 2010 Functionally, LMP1-mediated induction of TP expression enhanced the sensitivity of NPC cells to the chemotherapeutic prodrug, 5"-DFUR. doxifluridine 126-133 PDZ and LIM domain 7 Homo sapiens 14-18 21319009-12 2009 MINI-ABSTRACT: Combination therapy by trastuzumab with 5"-DFUR and cyclophosphamide can be safely administered on an outpatient basis and is useful to treat patients with HER2-overexpressing metastatic breast cancer. doxifluridine 55-62 erb-b2 receptor tyrosine kinase 2 Homo sapiens 171-175 18630517-0 2008 Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5"-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts. doxifluridine 137-161 thymidylate synthetase Homo sapiens 55-75 19091861-5 2009 Thymidine phosphorylase, a cellular enzyme markedly induced by ORFK13/vFLIP, can metabolize the prodrug 5-fluoro-5-deoxyuridine (5-dFUrd) to 5-fluouridine (5-FU), a potent thymidine synthase inhibitor, which blocks DNA and RNA synthesis. doxifluridine 104-127 K13 Human gammaherpesvirus 8 70-75 19091861-5 2009 Thymidine phosphorylase, a cellular enzyme markedly induced by ORFK13/vFLIP, can metabolize the prodrug 5-fluoro-5-deoxyuridine (5-dFUrd) to 5-fluouridine (5-FU), a potent thymidine synthase inhibitor, which blocks DNA and RNA synthesis. doxifluridine 129-136 K13 Human gammaherpesvirus 8 70-75 19091861-6 2009 When tested for cytotoxicity, 5-dFUrd (0.1 to 1 microM) selectively killed ORFK13/vFLIP-expressing endothelial cells while sparing control cells. doxifluridine 30-37 K13 Human gammaherpesvirus 8 82-87 19101214-1 2009 A novel 5"-deoxy-5-fluorouridine-poly(epsilon-caprolactone) (5"-DFUR-PCL) polymer was synthesized from the antitumor agent doxifluridine (5"-DFUR) by the ring-opening polymerization of epsilon-caprolactone (epsilon-CL) using Sn(II) 2-ethylhexanoate (Sn(Oct)2) as the catalyst. doxifluridine 123-136 POU class 2 homeobox 2 Homo sapiens 253-258 19101214-1 2009 A novel 5"-deoxy-5-fluorouridine-poly(epsilon-caprolactone) (5"-DFUR-PCL) polymer was synthesized from the antitumor agent doxifluridine (5"-DFUR) by the ring-opening polymerization of epsilon-caprolactone (epsilon-CL) using Sn(II) 2-ethylhexanoate (Sn(Oct)2) as the catalyst. doxifluridine 61-68 POU class 2 homeobox 2 Homo sapiens 253-258 19101214-4 2009 Two mechanisms of epsilon-CL polymerization initiated by Sn(Oct)2 were proposed involving either a single or two 5"-DFUR molecules. doxifluridine 113-120 POU class 2 homeobox 2 Homo sapiens 60-65 19117293-1 2009 OBJECTIVES: To evaluate whether two molecular biomarkers, thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD), could be clinically useful in predicting and improving the chemotherapeutic outcome of the oral fluoropyrimidine capecitabine (5"-DFUR or Xeloda), in the treatment of human head and neck squamous cell carcinoma (HNSCC). doxifluridine 257-264 dihydropyrimidine dehydrogenase Homo sapiens 124-127 18630517-0 2008 Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5"-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts. doxifluridine 137-161 dihydropyrimidine dehydrogenase Homo sapiens 77-108 18281707-0 2008 Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). doxifluridine 68-81 proteasome 26S subunit, non-ATPase 1 Homo sapiens 147-150 18281707-12 2008 CONCLUSIONS: The combination of paclitaxel and doxifluridine might be a treatment of choice as a second line chemotherapy for patient undergone S-1 treatment. doxifluridine 47-60 proteasome 26S subunit, non-ATPase 1 Homo sapiens 144-147 16897968-3 2006 As a single agent, S-1 showed higher antitumor activity with its low intestinal toxicity compared to continuous venous infusion 5-FU, the most effective dosing method of 5-FU, and/or to clinically available oral fluoropyrimidines such as UFT, doxyfluridine and capecitabine on various murine tumors and human tumor xenografts. doxifluridine 243-256 proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 Mus musculus 19-22 17988526-0 2007 [Interferon alpha enhances the sensitivity of SMMC-7721 hepatocellular carcinoma cells to 5"-deoxy-5-fluorouridine related to up-regulation of thymidine phosphorylase]. doxifluridine 90-114 thymidine phosphorylase Homo sapiens 143-166 17988526-1 2007 OBJECTIVE: To observe changes of sensitivity to 5"-deoxy-5-fluorouridine (5"-dFUrd), and 5-fluorouracil (5-FU) in SMMC-7721 hepatocellular carcinoma cells by interferon alpha (IFN-alpha), and its relationship with the expression of thymidine phosphorylase (TP). doxifluridine 48-72 interferon alpha 1 Homo sapiens 176-185 17988526-1 2007 OBJECTIVE: To observe changes of sensitivity to 5"-deoxy-5-fluorouridine (5"-dFUrd), and 5-fluorouracil (5-FU) in SMMC-7721 hepatocellular carcinoma cells by interferon alpha (IFN-alpha), and its relationship with the expression of thymidine phosphorylase (TP). doxifluridine 48-72 thymidine phosphorylase Homo sapiens 232-255 17988526-1 2007 OBJECTIVE: To observe changes of sensitivity to 5"-deoxy-5-fluorouridine (5"-dFUrd), and 5-fluorouracil (5-FU) in SMMC-7721 hepatocellular carcinoma cells by interferon alpha (IFN-alpha), and its relationship with the expression of thymidine phosphorylase (TP). doxifluridine 74-82 interferon alpha 1 Homo sapiens 176-185 17988526-1 2007 OBJECTIVE: To observe changes of sensitivity to 5"-deoxy-5-fluorouridine (5"-dFUrd), and 5-fluorouracil (5-FU) in SMMC-7721 hepatocellular carcinoma cells by interferon alpha (IFN-alpha), and its relationship with the expression of thymidine phosphorylase (TP). doxifluridine 74-82 thymidine phosphorylase Homo sapiens 232-255 17988526-7 2007 IFN-alpha enhanced the sensitivity of SMMC-7721 cells to 5"-dFUrd with dose-dependent increase. doxifluridine 57-65 interferon alpha 1 Homo sapiens 0-9 17988526-8 2007 IFN-alpha (10 000 U/ml) reduced IC(50) of 5"-dFUrd from (102.1 +/- 18.4) micromol/L to (34.2 +/- 4.1) micromol/L (P < 0.05). doxifluridine 42-50 interferon alpha 1 Homo sapiens 0-9 17988526-12 2007 CONCLUSION: IFN-alpha enhanced cytotoxicity of 5"-dFUrd against SMMC-7721 cells positively related to its induction of TP mRNA. doxifluridine 47-55 interferon alpha 1 Homo sapiens 12-21 17988526-12 2007 CONCLUSION: IFN-alpha enhanced cytotoxicity of 5"-dFUrd against SMMC-7721 cells positively related to its induction of TP mRNA. doxifluridine 47-55 thymidine phosphorylase Homo sapiens 119-121 17629045-0 2007 Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer. doxifluridine 125-138 dihydropyrimidine dehydrogenase Homo sapiens 40-71 17629045-9 2007 CONCLUSIONS: The DPD activity in the tumor may be a useful indicator for selecting patients likely respond to 5"-DFUR together with MMC as adjuvant chemotherapy. doxifluridine 110-117 dihydropyrimidine dehydrogenase Homo sapiens 17-20 16965766-0 2006 Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5"-DFUR in breast cancer MCF7 cells. doxifluridine 128-135 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 16965766-0 2006 Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5"-DFUR in breast cancer MCF7 cells. doxifluridine 128-135 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 16965766-6 2006 Although 5"-DFUR is a substrate for both plasma membrane equilibrative nucleoside carriers, hENT1 shows higher affinity for this molecule than hENT2. doxifluridine 9-16 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 92-97 16965766-7 2006 Inhibition of hENT1 function partially protected MCF7 cells from 5"-DFUR-induced cytotoxicity. doxifluridine 65-72 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-19 16965766-8 2006 Secondly, we have used a pharmacogenomic approach to determine how inhibition of hENT1 function contributes to the transcriptomic response associated to 5"-DFUR treatment. doxifluridine 153-160 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 81-86 16965766-10 2006 This study demonstrates that although 5"-DFUR is substrate for both equilibrative nucleoside carriers, hENT1 function is essential for the full transcriptional response to 5"-DFUR treatment. doxifluridine 172-179 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 103-108 16457948-9 2006 A TP inhibitor, TPI, abrogated the cytotoxic activity of 5"-DFUR, and attenuated the combined cytotoxicity of AZT and 5"-DFUR. doxifluridine 57-64 triosephosphate isomerase 1 Homo sapiens 16-19 16457948-9 2006 A TP inhibitor, TPI, abrogated the cytotoxic activity of 5"-DFUR, and attenuated the combined cytotoxicity of AZT and 5"-DFUR. doxifluridine 118-125 triosephosphate isomerase 1 Homo sapiens 16-19 16940802-8 2006 5"-Deoxy-5-fluorouridine with GW282974X demonstrated global synergy, both in high and low expressing epidermal growth factor receptor breast cancer cell lines. doxifluridine 0-24 epidermal growth factor receptor Homo sapiens 101-133 18053967-5 2008 Expression of hCNT1 slightly increased cell sensitivity to 5"-deoxy-5-fluorouridine (5"-DFUR). doxifluridine 59-83 solute carrier family 28 member 1 Homo sapiens 14-19 18053967-5 2008 Expression of hCNT1 slightly increased cell sensitivity to 5"-deoxy-5-fluorouridine (5"-DFUR). doxifluridine 85-92 solute carrier family 28 member 1 Homo sapiens 14-19 18053967-8 2008 To confirm the role of hCNT1 in 5"-DFUR treatment, a panel of nucleoside derivatives suitable for hCNT1-inhibition was obtained. doxifluridine 32-39 solute carrier family 28 member 1 Homo sapiens 23-28 18053967-10 2008 Furthermore, the cytotoxic action of 5"-DFUR and the transcriptional changes produced by this nucleoside analogue were partially inhibited by T-Ala in MCF7-hCNT1 cells. doxifluridine 37-44 solute carrier family 28 member 1 Homo sapiens 156-161 17016579-3 2006 We present a colon cancer patient with the UGT1A1 polymorphism (UGT1A1 *28) as a known high risk for irinotecan, who was treated with a combination of doxifluridine and irinotecan for peritoneal dissemination resulting in stable disease for 2 years without adverse reactions, although the patient initially developed severe adverse effects to the combination of the protracted venous infusion of 5-FU and irinotecan. doxifluridine 151-164 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 43-49 17016579-3 2006 We present a colon cancer patient with the UGT1A1 polymorphism (UGT1A1 *28) as a known high risk for irinotecan, who was treated with a combination of doxifluridine and irinotecan for peritoneal dissemination resulting in stable disease for 2 years without adverse reactions, although the patient initially developed severe adverse effects to the combination of the protracted venous infusion of 5-FU and irinotecan. doxifluridine 151-164 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 64-70 15864645-8 2005 CONCLUSION: Sensitivity to 5"-dFUrd could be enhanced by transfection with TP cDNA for SMMC-7721 cells. doxifluridine 27-35 thymidine phosphorylase Homo sapiens 75-77 16353181-1 2006 BACKGROUND AND OBJECTIVES: We have investigated the regulation by mitomycin C (MMC) of thymidine phosphorylase (dThdPase) and dihydropyrimidine dehydrogenase (DPD), which enhances or reduces the efficacy of capecitabine and its metabolite 5"-deoxy-5-fluorouridine (5"-DFUR), in rectal cancer tissues. doxifluridine 239-263 dihydropyrimidine dehydrogenase Homo sapiens 66-157 16353181-1 2006 BACKGROUND AND OBJECTIVES: We have investigated the regulation by mitomycin C (MMC) of thymidine phosphorylase (dThdPase) and dihydropyrimidine dehydrogenase (DPD), which enhances or reduces the efficacy of capecitabine and its metabolite 5"-deoxy-5-fluorouridine (5"-DFUR), in rectal cancer tissues. doxifluridine 265-272 dihydropyrimidine dehydrogenase Homo sapiens 66-157 16353181-8 2006 The disease free-survival rate in the Dukes B or C patients with a high dThdPase/DPD ratio in surgical specimen who received 5"-DFUR based adjuvant chemotherapy tended to be higher than that in those with a low dThdPase/DPD ratio. doxifluridine 125-132 dihydropyrimidine dehydrogenase Homo sapiens 81-84 16353181-8 2006 The disease free-survival rate in the Dukes B or C patients with a high dThdPase/DPD ratio in surgical specimen who received 5"-DFUR based adjuvant chemotherapy tended to be higher than that in those with a low dThdPase/DPD ratio. doxifluridine 125-132 dihydropyrimidine dehydrogenase Homo sapiens 220-223 16397116-0 2006 Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5"-deoxy-5-fluorouridine in breast cancer cells. doxifluridine 156-180 tumor necrosis factor Mus musculus 55-82 16397116-1 2006 Uridine phosphorylase (UPase) has been shown to play an important role in the antineoplastic activity of 5-fluorouracil (5-FU) and in the anabolism of its oral prodrug, capecitabine, through the conversion of 5"-deoxy-5-fluorouridine (5"-DFUR) into 5-FU. doxifluridine 209-233 uridine phosphorylase 1 Mus musculus 23-28 16397116-1 2006 Uridine phosphorylase (UPase) has been shown to play an important role in the antineoplastic activity of 5-fluorouracil (5-FU) and in the anabolism of its oral prodrug, capecitabine, through the conversion of 5"-deoxy-5-fluorouridine (5"-DFUR) into 5-FU. doxifluridine 235-242 uridine phosphorylase 1 Mus musculus 23-28 16397116-3 2006 Our data indicate that TNF-alpha significantly induced UPase mRNA expression and its enzymatic activity in EMT6 murine breast cancer cells, leading to an enhanced cytotoxicity of 5"-DFUR. doxifluridine 179-186 tumor necrosis factor Mus musculus 23-32 16397116-3 2006 Our data indicate that TNF-alpha significantly induced UPase mRNA expression and its enzymatic activity in EMT6 murine breast cancer cells, leading to an enhanced cytotoxicity of 5"-DFUR. doxifluridine 179-186 uridine phosphorylase 1 Mus musculus 55-60 16397116-9 2006 In summary, TNF-alpha efficiently induces UPase gene expression through a NF-kappaB subunit p65-dependent pathway enhancing cell sensitivity to 5"-DFUR. doxifluridine 144-151 tumor necrosis factor Mus musculus 12-21 16397116-9 2006 In summary, TNF-alpha efficiently induces UPase gene expression through a NF-kappaB subunit p65-dependent pathway enhancing cell sensitivity to 5"-DFUR. doxifluridine 144-151 uridine phosphorylase 1 Mus musculus 42-47 16397116-9 2006 In summary, TNF-alpha efficiently induces UPase gene expression through a NF-kappaB subunit p65-dependent pathway enhancing cell sensitivity to 5"-DFUR. doxifluridine 144-151 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 92-95 16552801-9 2006 However,the PCNA index (PI) in 5"-DFUR group (40.51+/-12.62) and 5-FU+CF group (41.12+/-15.26) was significantly lower than that in control group (58.33+/-15.69) (F=9.083, P=0.000). doxifluridine 31-38 proliferating cell nuclear antigen Homo sapiens 12-16 16552801-12 2006 Meanwhile, the expression rate of PD-ECGF was significantly lower in 5"-DFUR group (4/18,28.6%) than in CF+5-FU group(9/16,56.3%)and control group (13/20,65.0%) (chi2=7.542, P=0.023). doxifluridine 69-76 thymidine phosphorylase Homo sapiens 34-41 16552801-16 2006 CONCLUSION: Preoperative oral 5"-DFUR administration may induce apoptosis of gastric carcinoma cells and decrease tumor cell proliferation index,but cannot improve the prognosis of patients with gastric cancer.Down-regulation of FasL and PD-ECGF expression mediated by 5"-DFUR may be one of its anti-cancer mechanisms.Fas expression correlates with the progression of gastric carcinoma and may be an effective prognostic factor. doxifluridine 30-37 Fas ligand Homo sapiens 229-233 16552801-16 2006 CONCLUSION: Preoperative oral 5"-DFUR administration may induce apoptosis of gastric carcinoma cells and decrease tumor cell proliferation index,but cannot improve the prognosis of patients with gastric cancer.Down-regulation of FasL and PD-ECGF expression mediated by 5"-DFUR may be one of its anti-cancer mechanisms.Fas expression correlates with the progression of gastric carcinoma and may be an effective prognostic factor. doxifluridine 30-37 thymidine phosphorylase Homo sapiens 238-245 16552801-16 2006 CONCLUSION: Preoperative oral 5"-DFUR administration may induce apoptosis of gastric carcinoma cells and decrease tumor cell proliferation index,but cannot improve the prognosis of patients with gastric cancer.Down-regulation of FasL and PD-ECGF expression mediated by 5"-DFUR may be one of its anti-cancer mechanisms.Fas expression correlates with the progression of gastric carcinoma and may be an effective prognostic factor. doxifluridine 269-276 Fas ligand Homo sapiens 229-233 15628771-2 2004 In the meantime, TP and DPD are a converting enzyme of 5"-DFUR to 5-FU and the major catabolic enzyme of 5-FU, respectively. doxifluridine 55-62 dihydropyrimidine dehydrogenase Homo sapiens 24-27 15944764-6 2005 There were inverse correlations between antitumor and DPD activities for 5"-DFUR (r=-0.79, P=0.034), capecitabine (r=-0.56, P=0.19) and 5-FU (r=-0.86, P=0.013). doxifluridine 73-80 dihydropyrimidine dehydrogenase Homo sapiens 54-57 15729713-9 2005 The TP/DPD ratios measured in three cell lines correlated well with the cytotoxicity of 5"-deoxy-5-fluorouridine measured in vitro, indicating that the measurements are related to the biological activity of the drug. doxifluridine 88-112 dihydropyrimidine dehydrogenase Homo sapiens 7-10 15547701-8 2004 We identified two proto-oncogenes, nuclear receptor of T-cells (NOT) and c-fos, that were up-regulated in doxifluridine- and irinotecan-related regimens but unchanged in the 5-FU-related regimen. doxifluridine 106-119 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 73-78 15547701-10 2004 These results suggest that doxifluridine has a synergistic impact on the therapeutic effect of irinotecan by up-regulating proto-oncogenes such as NOT and c-fos, and thus justify the use of one of the irinotecan and fluoropyrimidine combinations. doxifluridine 27-40 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 155-160 15301717-0 2004 [Enhancement effect of interferon gamma on the sensitivity of RT4 bladder cancer cells to 5"-deoxy-5-fluorouridine,and 5-fluorouracil through up-regulation of PD-ECGF/TP]. doxifluridine 90-114 interferon gamma Homo sapiens 23-39 15446554-0 2004 [The association of expression and gene polymorphism of the thymidylate synthase gene with 5-fluoro-5"-deoxyuridine sensitivity in gastric cancer cell lines]. doxifluridine 91-115 thymidylate synthetase Homo sapiens 60-80 15301717-0 2004 [Enhancement effect of interferon gamma on the sensitivity of RT4 bladder cancer cells to 5"-deoxy-5-fluorouridine,and 5-fluorouracil through up-regulation of PD-ECGF/TP]. doxifluridine 90-114 thymidine phosphorylase Homo sapiens 159-166 15301717-1 2004 BACKGROUND & OBJECTIVE: Platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) is an essential enzyme in converting 5"-deoxy-5-fluorouridine (5"-DFUR), and 5-fluorouracil (5-FU) to their active metabolites in vivo, and can be up-regulated by some cytokines such as interleukin-1, and interferon gamma (INFgamma). doxifluridine 150-174 thymidine phosphorylase Homo sapiens 101-111 15301717-1 2004 BACKGROUND & OBJECTIVE: Platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) is an essential enzyme in converting 5"-deoxy-5-fluorouridine (5"-DFUR), and 5-fluorouracil (5-FU) to their active metabolites in vivo, and can be up-regulated by some cytokines such as interleukin-1, and interferon gamma (INFgamma). doxifluridine 150-174 interferon gamma Homo sapiens 318-334 15301717-1 2004 BACKGROUND & OBJECTIVE: Platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) is an essential enzyme in converting 5"-deoxy-5-fluorouridine (5"-DFUR), and 5-fluorouracil (5-FU) to their active metabolites in vivo, and can be up-regulated by some cytokines such as interleukin-1, and interferon gamma (INFgamma). doxifluridine 176-183 thymidine phosphorylase Homo sapiens 101-111 15301717-1 2004 BACKGROUND & OBJECTIVE: Platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) is an essential enzyme in converting 5"-deoxy-5-fluorouridine (5"-DFUR), and 5-fluorouracil (5-FU) to their active metabolites in vivo, and can be up-regulated by some cytokines such as interleukin-1, and interferon gamma (INFgamma). doxifluridine 176-183 interferon gamma Homo sapiens 318-334 15301717-2 2004 This study was to observe the regulative effect of INFgamma on expression of PD-ECGF/TP, and its relation with the anti-cancer effect of 5"-DFUR, and 5-FU on RT4 bladder cancer cells. doxifluridine 137-144 thymidine phosphorylase Homo sapiens 77-84 15301717-7 2004 CONCLUSIONS: INFgamma enhances cytotoxicity of 5"-DFUR, and 5-FU against RT4 cells through induction of PD-ECGF/TP. doxifluridine 47-54 thymidine phosphorylase Homo sapiens 104-111 15200906-19 2004 After incubated with THP-1 or U937, 5"-DFUR expressed a significant enhanced antitumor effect (P < 0.0001), while almost no change is observed to 5-Fu (P > 0.05). doxifluridine 36-43 GLI family zinc finger 2 Homo sapiens 21-26 15196541-0 2004 The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5"-deoxy-5-fluorouridine. doxifluridine 175-199 dihydropyrimidine dehydrogenase Homo sapiens 40-71 15196541-1 2004 The aim of this work was to determine whether intratumour contents of thymidine phosphorylase (TP), which converts 5"-deoxy-5-fluorouridine (5"-DFUR) to 5-fluorouracil, and dihydropyrimidine dehydrogenase (DPD), which degrades 5-fluorouracil to inactive molecules, could be useful in predicting the response of patients with metastatic gastric cancer to chemotherapy using 5"-DFUR. doxifluridine 141-148 dihydropyrimidine dehydrogenase Homo sapiens 173-204 15196541-1 2004 The aim of this work was to determine whether intratumour contents of thymidine phosphorylase (TP), which converts 5"-deoxy-5-fluorouridine (5"-DFUR) to 5-fluorouracil, and dihydropyrimidine dehydrogenase (DPD), which degrades 5-fluorouracil to inactive molecules, could be useful in predicting the response of patients with metastatic gastric cancer to chemotherapy using 5"-DFUR. doxifluridine 141-148 dihydropyrimidine dehydrogenase Homo sapiens 206-209 15196541-10 2004 The efficacy of 5"-DFUR could be optimised by preselecting patients with high TP/ DPD ratios in their tumour tissues, and this would be applicable to the treatment with capecitabine. doxifluridine 16-23 dihydropyrimidine dehydrogenase Homo sapiens 82-85 15201953-0 2004 Prediction of 5"-deoxy-5-fluorouridine sensitivity in colorectal cancer cases by thymidine phosphorylase activity and preliminary identification of susceptibility related genes. doxifluridine 14-38 thymidine phosphorylase Homo sapiens 81-104 15201953-1 2004 We confirmed that the enzyme activity of thymidine phosphorylase (TP) can substitute for 5"-deoxy-5-fluorouridine (5"-dFUR) sensitivity in clinical colorectal cancer (CRC) tissues. doxifluridine 89-113 thymidine phosphorylase Homo sapiens 41-64 15201953-1 2004 We confirmed that the enzyme activity of thymidine phosphorylase (TP) can substitute for 5"-deoxy-5-fluorouridine (5"-dFUR) sensitivity in clinical colorectal cancer (CRC) tissues. doxifluridine 89-113 thymidine phosphorylase Homo sapiens 66-68 15201953-1 2004 We confirmed that the enzyme activity of thymidine phosphorylase (TP) can substitute for 5"-deoxy-5-fluorouridine (5"-dFUR) sensitivity in clinical colorectal cancer (CRC) tissues. doxifluridine 115-122 thymidine phosphorylase Homo sapiens 41-64 15201953-1 2004 We confirmed that the enzyme activity of thymidine phosphorylase (TP) can substitute for 5"-deoxy-5-fluorouridine (5"-dFUR) sensitivity in clinical colorectal cancer (CRC) tissues. doxifluridine 115-122 thymidine phosphorylase Homo sapiens 66-68 15201953-2 2004 Moreover, the idenfication of susceptible genes other than TP will be desired for prediction or treatment of 5"-dFUR. doxifluridine 109-116 thymidine phosphorylase Homo sapiens 59-61 15201953-4 2004 TP activity levels were concordant with 5"-dFUR sensitivity in the CRCs (p<0.05). doxifluridine 40-47 thymidine phosphorylase Homo sapiens 0-2 15200906-21 2004 40.2 micro mol/L and 29.5 micro mol/L of 5-Fu were detected in the medium containing 400 micro mol/L of 5"-DFUR treated with THP-1 and U937 cells, respectively. doxifluridine 104-111 GLI family zinc finger 2 Homo sapiens 125-130 15200906-23 2004 After being incubated with macrophage-like cell, THP-1, U937, or human monocytes, the anticancer effect of 5"-DFUR is significantly increased due to the activation by dThdPase expressed in above cells. doxifluridine 107-114 GLI family zinc finger 2 Homo sapiens 49-54 15114696-2 2004 Dihydropyrimidine dehydrogenase (DPD) which catalyzes 5-fluorouracil (5-FU), thymidine phosphorylase (TP), responsible for catalyzing doxifluridine to 5-FU, and thymidylate synthase (TS) were estimated for breast cancer. doxifluridine 134-147 dihydropyrimidine dehydrogenase Homo sapiens 0-31 15231865-3 2004 We describe a 66-year-old woman in whom S-1 induced complete regression of lung metastasis from gastric cancer, that had been refractory to another oral fluoropyrimidine, 5"-deoxy-5-fluorouridine (5"-DFUR). doxifluridine 171-195 proteasome 26S subunit, non-ATPase 1 Homo sapiens 40-43 15231865-3 2004 We describe a 66-year-old woman in whom S-1 induced complete regression of lung metastasis from gastric cancer, that had been refractory to another oral fluoropyrimidine, 5"-deoxy-5-fluorouridine (5"-DFUR). doxifluridine 197-204 proteasome 26S subunit, non-ATPase 1 Homo sapiens 40-43 15446554-9 2004 In this subgroup, the cell lines with higher TS protein showed higher IC50 value for 5"-dFUrd, indicating less sensitivity to 5"-dFUrd. doxifluridine 85-93 thymidylate synthetase Homo sapiens 45-47 15446554-9 2004 In this subgroup, the cell lines with higher TS protein showed higher IC50 value for 5"-dFUrd, indicating less sensitivity to 5"-dFUrd. doxifluridine 126-134 thymidylate synthetase Homo sapiens 45-47 15231865-0 2004 S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5"-DFUR: a case report with pharmacokinetic study. doxifluridine 96-103 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 15114696-2 2004 Dihydropyrimidine dehydrogenase (DPD) which catalyzes 5-fluorouracil (5-FU), thymidine phosphorylase (TP), responsible for catalyzing doxifluridine to 5-FU, and thymidylate synthase (TS) were estimated for breast cancer. doxifluridine 134-147 dihydropyrimidine dehydrogenase Homo sapiens 33-36 15114696-2 2004 Dihydropyrimidine dehydrogenase (DPD) which catalyzes 5-fluorouracil (5-FU), thymidine phosphorylase (TP), responsible for catalyzing doxifluridine to 5-FU, and thymidylate synthase (TS) were estimated for breast cancer. doxifluridine 134-147 thymidylate synthetase Homo sapiens 161-181 15114696-2 2004 Dihydropyrimidine dehydrogenase (DPD) which catalyzes 5-fluorouracil (5-FU), thymidine phosphorylase (TP), responsible for catalyzing doxifluridine to 5-FU, and thymidylate synthase (TS) were estimated for breast cancer. doxifluridine 134-147 thymidylate synthetase Homo sapiens 183-185 15604581-8 2004 Thymidine phosphorylase (TP), the enzyme that converts 5"-DFUR into 5-FU and 5-FU into FdUMP, was estimated by ELISA. doxifluridine 55-62 thymidine phosphorylase Homo sapiens 0-23 15062035-2 2004 METHODS: During the induction phase of the treatment of 28 patients, which lasted 3 months, IL-2 and IFN were administered subcutaneously three times a week at doses of 5 - 20 MU/m(2) and 6 - 9 MU/m(2), Furtulon was administered at doses of 800 - 1,200 mg daily by oral during 28 days a month. doxifluridine 203-211 interleukin 2 Homo sapiens 92-104 14614573-9 2004 CONCLUSION: The increased TP expression and the elevated TP/DPD ratio following irradiation with up to 20 Gy may offer an increased clinical advantage to chemoradiotherapy with capecitabine or doxyfluridine over radiotherapy alone. doxifluridine 193-206 thymidine phosphorylase Homo sapiens 26-28 14614573-9 2004 CONCLUSION: The increased TP expression and the elevated TP/DPD ratio following irradiation with up to 20 Gy may offer an increased clinical advantage to chemoradiotherapy with capecitabine or doxyfluridine over radiotherapy alone. doxifluridine 193-206 dihydropyrimidine dehydrogenase Homo sapiens 57-63 15604581-8 2004 Thymidine phosphorylase (TP), the enzyme that converts 5"-DFUR into 5-FU and 5-FU into FdUMP, was estimated by ELISA. doxifluridine 55-62 thymidine phosphorylase Homo sapiens 25-27 15604581-11 2004 On the other hand, in the high TP expression group, TP expression was enhanced by IFNalpha in 5 out of 6 cell lines, and antitumor effects were enhanced by IFNalpha in 5 out of 6 cell lines for 5-FU and in all 6 cell lines for 5"-DFUR. doxifluridine 227-234 thymidine phosphorylase Homo sapiens 31-33 15604581-13 2004 CONCLUSIONS: These results suggested that TP may be useful as a predictive factor in combination therapy with IFNalpha and 5-FU or 5"-DFUR, which may be a promising treatment for advanced RCC. doxifluridine 131-138 thymidine phosphorylase Homo sapiens 42-44 12894555-12 2003 CONCLUSION: Our results show that a low concentration of Taxol is a candidate for increasing TP expression in a human ovarian carcinoma cell line, and that cells with an elevated level of TP expression can be further sensitized to Furtulon. doxifluridine 231-239 thymidine phosphorylase Homo sapiens 188-190 14639009-4 2003 Cytidine deaminase(CD), an enzyme found in most tissues, including tumors, subsequently converts 5"-DFCR to 5"-deoxy-5-fluorouridine (5"-DFUR). doxifluridine 108-132 cytidine deaminase Homo sapiens 0-18 14639009-4 2003 Cytidine deaminase(CD), an enzyme found in most tissues, including tumors, subsequently converts 5"-DFCR to 5"-deoxy-5-fluorouridine (5"-DFUR). doxifluridine 134-141 cytidine deaminase Homo sapiens 0-18 14518422-0 2003 [PyNPase and DPD expression potentially predict response to 5"-DFUR treatment for node-positive breast cancer patients]. doxifluridine 60-67 dihydropyrimidine dehydrogenase Homo sapiens 13-16 14518422-1 2003 Pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) activity may be related of the antitumor effect of 5"-deoxy-5-fluorouridine (5"-DFUR). doxifluridine 139-163 dihydropyrimidine dehydrogenase Homo sapiens 50-81 14518422-1 2003 Pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) activity may be related of the antitumor effect of 5"-deoxy-5-fluorouridine (5"-DFUR). doxifluridine 139-163 dihydropyrimidine dehydrogenase Homo sapiens 83-86 14518422-1 2003 Pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) activity may be related of the antitumor effect of 5"-deoxy-5-fluorouridine (5"-DFUR). doxifluridine 165-172 dihydropyrimidine dehydrogenase Homo sapiens 50-81 14518422-1 2003 Pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) activity may be related of the antitumor effect of 5"-deoxy-5-fluorouridine (5"-DFUR). doxifluridine 165-172 dihydropyrimidine dehydrogenase Homo sapiens 83-86 12883718-5 2003 TS and DPD mRNA levels, which correlated to the corresponding enzyme activities, were quantified in tumor tissues before and after treatment in 40 advanced colorectal cancer patients who had been treated with Doxifluridine (5"-DFUR) for 14 days before surgery. doxifluridine 224-231 thymidylate synthetase Homo sapiens 0-2 14641294-1 2003 Pyrimidine nucleoside phosphorylase (PyNPase) converts 5"-deoxy-5-fluorouridine to 5"-fluorouracil, which exerts an anticancer effect before being catabolized by dihydropyrimidine dehydrogenase (DPD). doxifluridine 55-79 dihydropyrimidine dehydrogenase Homo sapiens 162-193 12556409-0 2003 Subconjunctival doxifluridine administration suppresses rat choroidal neovascularization through activated thymidine phosphorylase. doxifluridine 16-29 thymidine phosphorylase Rattus norvegicus 107-130 12556409-1 2003 PURPOSE: Doxifluridine (5"-deoxy 5-fluorouridine) is an oral anticancer drug with antiangiogenic effects, with vasoclastic action that is enhanced by a major member of the pyrimidine phosphorylases, thymidine phosphorylase (TP). doxifluridine 9-22 thymidine phosphorylase Rattus norvegicus 199-222 12556409-1 2003 PURPOSE: Doxifluridine (5"-deoxy 5-fluorouridine) is an oral anticancer drug with antiangiogenic effects, with vasoclastic action that is enhanced by a major member of the pyrimidine phosphorylases, thymidine phosphorylase (TP). doxifluridine 9-22 thymidine phosphorylase Rattus norvegicus 224-226 12556409-1 2003 PURPOSE: Doxifluridine (5"-deoxy 5-fluorouridine) is an oral anticancer drug with antiangiogenic effects, with vasoclastic action that is enhanced by a major member of the pyrimidine phosphorylases, thymidine phosphorylase (TP). doxifluridine 24-48 thymidine phosphorylase Rattus norvegicus 199-222 12556409-1 2003 PURPOSE: Doxifluridine (5"-deoxy 5-fluorouridine) is an oral anticancer drug with antiangiogenic effects, with vasoclastic action that is enhanced by a major member of the pyrimidine phosphorylases, thymidine phosphorylase (TP). doxifluridine 24-48 thymidine phosphorylase Rattus norvegicus 224-226 14641294-1 2003 Pyrimidine nucleoside phosphorylase (PyNPase) converts 5"-deoxy-5-fluorouridine to 5"-fluorouracil, which exerts an anticancer effect before being catabolized by dihydropyrimidine dehydrogenase (DPD). doxifluridine 55-79 dihydropyrimidine dehydrogenase Homo sapiens 195-198 12451471-4 2002 RESULTS: Liver microsomes catalyzed 5-FU formation from 5"-DFUR at rates of 10.0-160.1 pmol/min per mg protein and correlated well with CYP2A6-dependent coumarin 7-hydroxylase activity. doxifluridine 56-63 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 136-142 12625878-1 2003 It has been found in clinical practice that the serum level of phenytoin, of which metabolism is mediated by hepatic CYP2C enzymes, was markedly elevated by co-administration of 5-fluorouracil (5-FU) and doxifluridine (5"-deoxy-5-fluorouridine; 5"-DFUR), a prodrug of 5-FU, but the detailed mechanisms are unclear. doxifluridine 204-217 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 117-122 12625878-1 2003 It has been found in clinical practice that the serum level of phenytoin, of which metabolism is mediated by hepatic CYP2C enzymes, was markedly elevated by co-administration of 5-fluorouracil (5-FU) and doxifluridine (5"-deoxy-5-fluorouridine; 5"-DFUR), a prodrug of 5-FU, but the detailed mechanisms are unclear. doxifluridine 219-243 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 117-122 12625878-1 2003 It has been found in clinical practice that the serum level of phenytoin, of which metabolism is mediated by hepatic CYP2C enzymes, was markedly elevated by co-administration of 5-fluorouracil (5-FU) and doxifluridine (5"-deoxy-5-fluorouridine; 5"-DFUR), a prodrug of 5-FU, but the detailed mechanisms are unclear. doxifluridine 245-252 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 117-122 12931018-9 2003 The present finding of a wide range in these enzyme expressions in RCC suggests that a certain subpopulation with a high TP/DPD ratio has potential responsiveness to fluoropyrimidines, especially 5"-deoxy-5-fluorouridine and capecitabine. doxifluridine 196-220 dihydropyrimidine dehydrogenase Homo sapiens 124-127 12451471-4 2002 RESULTS: Liver microsomes catalyzed 5-FU formation from 5"-DFUR at rates of 10.0-160.1 pmol/min per mg protein and correlated well with CYP2A6-dependent coumarin 7-hydroxylase activity. doxifluridine 56-63 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 153-175 12460781-1 2002 This study was designed to investigate the role of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) on tumour progression and sensitivity to 5"-deoxy-5-fluorouridine (5"-DFUR). doxifluridine 163-187 dihydropyrimidine dehydrogenase Homo sapiens 117-120 12460781-6 2002 In comparison with 5"-DFUR sensitivity, there was a weak inverse correlation between the DPD level and the sensitivity to 5"-DFUR (r(s)=-0.361). doxifluridine 122-129 dihydropyrimidine dehydrogenase Homo sapiens 89-92 12460781-7 2002 Furthermore, the TP/DPD ratio showed a significant correlation with 5"-DFUR sensitivity (r(s)=0.634). doxifluridine 68-75 dihydropyrimidine dehydrogenase Homo sapiens 20-23 12460781-8 2002 In a subgroup of patients with postoperative 5"-DFUR administration, the survival rate was significantly better in patients with a high TP/DPD ratio (n=8) than in those with low TP/DPD ratio (n=14) (P=0.0140). doxifluridine 45-52 dihydropyrimidine dehydrogenase Homo sapiens 139-142 12460781-8 2002 In a subgroup of patients with postoperative 5"-DFUR administration, the survival rate was significantly better in patients with a high TP/DPD ratio (n=8) than in those with low TP/DPD ratio (n=14) (P=0.0140). doxifluridine 45-52 dihydropyrimidine dehydrogenase Homo sapiens 181-184 12460781-9 2002 These results suggest that sensitivity to 5"-DFUR is predictable by measurement of both TP and DPD levels. doxifluridine 42-49 dihydropyrimidine dehydrogenase Homo sapiens 95-98 12553027-5 2002 Thymidine phosphorylase (TP), the enzyme that converts 5"-DFUR into 5-FU and 5-FU into 5-fluoro-2"-deoxyuridine-5"-monophosphate (FdUMP), was estimated by ELISA. doxifluridine 55-62 thymidine phosphorylase Homo sapiens 0-23 12553027-5 2002 Thymidine phosphorylase (TP), the enzyme that converts 5"-DFUR into 5-FU and 5-FU into 5-fluoro-2"-deoxyuridine-5"-monophosphate (FdUMP), was estimated by ELISA. doxifluridine 55-62 thymidine phosphorylase Homo sapiens 25-27 12553027-6 2002 As a result, a significant correlation between TP expression and sensitivity to 5-FU and 5"-DFUR was found in all 4 RCC cell lines. doxifluridine 89-96 thymidine phosphorylase Homo sapiens 47-49 12408764-2 2002 METHODS: Expression of ERK-1 and ERK-2 protein was examined by Western blot in the breast cancer and normal breast (control) tissue of 48 patients, of whom 8 had received preoperative chemotherapy of 5"-deoxy-5-fluorouridine (5"-DFUR), with distribution of ERKs protein detected by immunohistochemical method. doxifluridine 200-224 mitogen-activated protein kinase 3 Homo sapiens 23-28 12529971-0 2002 IFN gamma-induced up-regulation of PD-ECGF/TP enhances the cytotoxicity of 5-fluorouracil and 5"-deoxy-5-fluorouridine in bladder cancer cells. doxifluridine 94-118 interferon gamma Homo sapiens 0-9 12529971-0 2002 IFN gamma-induced up-regulation of PD-ECGF/TP enhances the cytotoxicity of 5-fluorouracil and 5"-deoxy-5-fluorouridine in bladder cancer cells. doxifluridine 94-118 thymidine phosphorylase Homo sapiens 35-42 12408764-2 2002 METHODS: Expression of ERK-1 and ERK-2 protein was examined by Western blot in the breast cancer and normal breast (control) tissue of 48 patients, of whom 8 had received preoperative chemotherapy of 5"-deoxy-5-fluorouridine (5"-DFUR), with distribution of ERKs protein detected by immunohistochemical method. doxifluridine 200-224 mitogen-activated protein kinase 1 Homo sapiens 33-38 12408764-2 2002 METHODS: Expression of ERK-1 and ERK-2 protein was examined by Western blot in the breast cancer and normal breast (control) tissue of 48 patients, of whom 8 had received preoperative chemotherapy of 5"-deoxy-5-fluorouridine (5"-DFUR), with distribution of ERKs protein detected by immunohistochemical method. doxifluridine 226-233 mitogen-activated protein kinase 3 Homo sapiens 23-28 12408764-2 2002 METHODS: Expression of ERK-1 and ERK-2 protein was examined by Western blot in the breast cancer and normal breast (control) tissue of 48 patients, of whom 8 had received preoperative chemotherapy of 5"-deoxy-5-fluorouridine (5"-DFUR), with distribution of ERKs protein detected by immunohistochemical method. doxifluridine 226-233 mitogen-activated protein kinase 1 Homo sapiens 33-38 12408764-6 2002 Expression of both ERK-1 and ERK-2 in the carcinoma tissue was decreased in patients who had received preoperative chemotherapy of 5"-DFUR. doxifluridine 131-138 mitogen-activated protein kinase 3 Homo sapiens 19-24 12408764-6 2002 Expression of both ERK-1 and ERK-2 in the carcinoma tissue was decreased in patients who had received preoperative chemotherapy of 5"-DFUR. doxifluridine 131-138 mitogen-activated protein kinase 1 Homo sapiens 29-34 12408764-9 2002 Preoperative chemotherapy of 5"-DFUR is able to partially inhibit ERK expression. doxifluridine 29-36 mitogen-activated protein kinase 1 Homo sapiens 66-69 11956613-0 2002 Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5"-deoxy-5-fluorouridine as adjuvant chemotherapy. doxifluridine 139-163 dihydropyrimidine dehydrogenase Homo sapiens 28-59 11956613-9 2002 These results suggest that TP and DPD levels in primary colorectal tumors may be a useful indicator for selecting patients likely to respond to 5"-DFUR adjuvant chemotherapy and probably capecitabine, a prodrug of 5"-DFUR. doxifluridine 144-151 dihydropyrimidine dehydrogenase Homo sapiens 34-37 11956613-9 2002 These results suggest that TP and DPD levels in primary colorectal tumors may be a useful indicator for selecting patients likely to respond to 5"-DFUR adjuvant chemotherapy and probably capecitabine, a prodrug of 5"-DFUR. doxifluridine 214-221 dihydropyrimidine dehydrogenase Homo sapiens 34-37 12016389-6 2002 CONCLUSIONS: Our findings suggest that tamoxifen may increase chemotherapy sensitivity through TP up-regulation for treatment regimens including doxifluridine, capecitabine, and/or methotrexate. doxifluridine 145-158 thymidine phosphorylase Homo sapiens 95-97 11935213-10 2002 However, observed additive in vivo antitumor activity clearly indicates that the clinical efficacy of the combination of trastuzumab and capecitabine/5"-dFUrd against HER-2-overexpressing breast cancer is worth investigating. doxifluridine 150-158 erb-b2 receptor tyrosine kinase 2 Homo sapiens 167-172 11956089-7 2002 Our data also shows the effect of UPase on the cytotoxicity of 5"-deoxy-5-fluorouridine (5"DFUR), a 5-FU prodrug. doxifluridine 63-87 uridine phosphorylase 1 Mus musculus 34-39 11956089-7 2002 Our data also shows the effect of UPase on the cytotoxicity of 5"-deoxy-5-fluorouridine (5"DFUR), a 5-FU prodrug. doxifluridine 89-95 uridine phosphorylase 1 Mus musculus 34-39 12020396-2 2002 Thymidine phosphorylase (TP) converts 5"-deoxy-5-fluorouridine (5"-DFUR), an intermediate metabolite of capecitabine, to 5-FU. doxifluridine 38-62 thymidine phosphorylase Homo sapiens 0-23 12020396-2 2002 Thymidine phosphorylase (TP) converts 5"-deoxy-5-fluorouridine (5"-DFUR), an intermediate metabolite of capecitabine, to 5-FU. doxifluridine 38-62 thymidine phosphorylase Homo sapiens 25-27 12020396-2 2002 Thymidine phosphorylase (TP) converts 5"-deoxy-5-fluorouridine (5"-DFUR), an intermediate metabolite of capecitabine, to 5-FU. doxifluridine 64-71 thymidine phosphorylase Homo sapiens 0-23 12020396-2 2002 Thymidine phosphorylase (TP) converts 5"-deoxy-5-fluorouridine (5"-DFUR), an intermediate metabolite of capecitabine, to 5-FU. doxifluridine 64-71 thymidine phosphorylase Homo sapiens 25-27 12020396-3 2002 The relationship between TP expression in tumor tissues and patient survival was retrospectively examined in early-stage breast cancer patients treated with either oral 5"-DFUR administered for 6 months or surgery alone in a prospective randomized controlled trial. doxifluridine 169-176 thymidine phosphorylase Homo sapiens 25-27 12020396-5 2002 Eight-year follow-up data showed that high TP expression in tumor cells was a significant prognostic indicator of a favorable outcome only for the patients in the 5"-DFUR group. doxifluridine 163-170 thymidine phosphorylase Homo sapiens 43-45 12020396-8 2002 These results on TP status in 2 tumor cell types could provide novel information for predicting prognosis for a patient subgroup, which would receive a probable therapeutic effect from 5"-DFUR, and presumably, from adjuvant therapy of capecitabine in early-stage breast cancer. doxifluridine 185-192 thymidine phosphorylase Homo sapiens 17-19 11801546-4 2002 The presence of NBMPR reduced the cytotoxic effects of 5"-deoxy-5-fluorouridine, indicating that hENT1 also enabled cellular uptake of this capecitabine metabolite by breast cancer cells. doxifluridine 55-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 97-102 11353816-5 2001 The two-electrode voltage-clamp technique was used to demonstrate that 5"-DFUR, but not capecitabine or 5"-FU, is an hCNT1 substrate. doxifluridine 71-78 solute carrier family 28 member 1 Homo sapiens 117-122 11562746-1 2001 Thymidine phosphorylase (TP) is an enzyme which converts doxifluridine (5"-DFUR) to 5-fluorouracil (5-FU). doxifluridine 57-70 thymidine phosphorylase Homo sapiens 0-23 11562746-1 2001 Thymidine phosphorylase (TP) is an enzyme which converts doxifluridine (5"-DFUR) to 5-fluorouracil (5-FU). doxifluridine 57-70 thymidine phosphorylase Homo sapiens 25-27 11562746-1 2001 Thymidine phosphorylase (TP) is an enzyme which converts doxifluridine (5"-DFUR) to 5-fluorouracil (5-FU). doxifluridine 72-79 thymidine phosphorylase Homo sapiens 0-23 11562746-1 2001 Thymidine phosphorylase (TP) is an enzyme which converts doxifluridine (5"-DFUR) to 5-fluorouracil (5-FU). doxifluridine 72-79 thymidine phosphorylase Homo sapiens 25-27 11562746-5 2001 When we compared prognosis in two chemotherapy groups with high TP expression, better survival was observed in 5"-DFUR than in 5-FU group (p=0.0413). doxifluridine 111-118 thymidine phosphorylase Homo sapiens 64-66 11562746-6 2001 Especially in stage III, patients with high TP had better survival in 5"-DFUR than in 5-FU group. doxifluridine 70-77 thymidine phosphorylase Homo sapiens 44-46 11353816-8 2001 hCNT1-expressing cells were more sensitive to 5"-DFUR than vector-transfected or wild-type cells. doxifluridine 46-53 solute carrier family 28 member 1 Homo sapiens 0-5 11353816-10 2001 In conclusion, this study shows that 1) the pharmacological profile of a nucleoside transporter can be determined by an electrophysiological approach; 2) the hCNT1 transporter is involved in 5"-DFUR uptake; and 3) hCNT1 expression may increase cell sensitivity to 5"-DFUR treatment. doxifluridine 191-198 solute carrier family 28 member 1 Homo sapiens 158-163 11353816-10 2001 In conclusion, this study shows that 1) the pharmacological profile of a nucleoside transporter can be determined by an electrophysiological approach; 2) the hCNT1 transporter is involved in 5"-DFUR uptake; and 3) hCNT1 expression may increase cell sensitivity to 5"-DFUR treatment. doxifluridine 191-198 solute carrier family 28 member 1 Homo sapiens 214-219 11353816-10 2001 In conclusion, this study shows that 1) the pharmacological profile of a nucleoside transporter can be determined by an electrophysiological approach; 2) the hCNT1 transporter is involved in 5"-DFUR uptake; and 3) hCNT1 expression may increase cell sensitivity to 5"-DFUR treatment. doxifluridine 264-271 solute carrier family 28 member 1 Homo sapiens 158-163 11353816-10 2001 In conclusion, this study shows that 1) the pharmacological profile of a nucleoside transporter can be determined by an electrophysiological approach; 2) the hCNT1 transporter is involved in 5"-DFUR uptake; and 3) hCNT1 expression may increase cell sensitivity to 5"-DFUR treatment. doxifluridine 264-271 solute carrier family 28 member 1 Homo sapiens 214-219 11302344-1 2001 BACKGROUND: Pyrimidine nucleoside phosphorylase (PyNPase) converts 5"-deoxy-5-fluorouridine (5"-DFUR) to 5"-fluorouracil (5-FU), which exerts an anti-cancer effect before being catabolized by dihydropyrimidine dehydrogenase (DPD). doxifluridine 67-91 dihydropyrimidine dehydrogenase Homo sapiens 192-223 11383213-11 2001 PyNPase/DPD suggests not only the malignant potential of the tumor but also the efficiency of chemotherapy using 5-FU, especially 5"-DFUR. doxifluridine 130-137 dihydropyrimidine dehydrogenase Homo sapiens 8-11 11302344-1 2001 BACKGROUND: Pyrimidine nucleoside phosphorylase (PyNPase) converts 5"-deoxy-5-fluorouridine (5"-DFUR) to 5"-fluorouracil (5-FU), which exerts an anti-cancer effect before being catabolized by dihydropyrimidine dehydrogenase (DPD). doxifluridine 67-91 dihydropyrimidine dehydrogenase Homo sapiens 225-228 11302344-1 2001 BACKGROUND: Pyrimidine nucleoside phosphorylase (PyNPase) converts 5"-deoxy-5-fluorouridine (5"-DFUR) to 5"-fluorouracil (5-FU), which exerts an anti-cancer effect before being catabolized by dihydropyrimidine dehydrogenase (DPD). doxifluridine 93-100 dihydropyrimidine dehydrogenase Homo sapiens 192-223 11302344-1 2001 BACKGROUND: Pyrimidine nucleoside phosphorylase (PyNPase) converts 5"-deoxy-5-fluorouridine (5"-DFUR) to 5"-fluorouracil (5-FU), which exerts an anti-cancer effect before being catabolized by dihydropyrimidine dehydrogenase (DPD). doxifluridine 93-100 dihydropyrimidine dehydrogenase Homo sapiens 225-228 11302344-7 2001 The PyNPase/DPD ratio, which is known to be correlated with the tissue concentration of 5"-DFUR, was higher in the tumor than in the normal tissue (p = 0.001). doxifluridine 88-95 dihydropyrimidine dehydrogenase Homo sapiens 12-15 10436411-3 1999 It is administrated orally and after absorption it is first metabolized to 5"-deoxy-5-fluorocytidine (5"-DFCR) by carboxylesterase from the liver and then converted to 5"-deoxy-5-fluorouridine (5"-DFUR) by cytidine deaminase from the liver and tumor tissues. doxifluridine 168-192 cytidine deaminase Homo sapiens 206-224 10976516-4 2000 Those were then converted to 5"-deoxy-5-fluorouridine (5"-DFUR: 4) by cytidine deaminase highly expressed in the liver and solid tumors and finally to 5-FU by thymidine phosphorylase (dThdPase) preferentially located in tumors. doxifluridine 29-53 cytidine deaminase Homo sapiens 70-88 10976516-4 2000 Those were then converted to 5"-deoxy-5-fluorouridine (5"-DFUR: 4) by cytidine deaminase highly expressed in the liver and solid tumors and finally to 5-FU by thymidine phosphorylase (dThdPase) preferentially located in tumors. doxifluridine 55-62 cytidine deaminase Homo sapiens 70-88 10772124-3 2000 A 68-year-old man with AFP-producing gastric cancer was treated with cisplatin and doxifluridine because of multiple liver metastases. doxifluridine 83-96 alpha fetoprotein Homo sapiens 23-26 11029783-6 2000 Our other studies have revealed that 5"-fluorouridine (5"-DFUR) inhibits the growth of KPL-4 tumors and decreases IL-6 levels in both serum and tumor tissues. doxifluridine 55-62 interleukin 6 Homo sapiens 114-118 11029783-8 2000 Docetaxel increased IL-6 levels in both serum and KPL-4 tumors, but combined treatment with docetaxel and 5"-DFUR resulted not only in a potent antitumor effect but also in a drastic decrease of serum IL-6 levels. doxifluridine 106-113 interleukin 6 Homo sapiens 201-205 10630095-3 1999 The first step is the conversion to 5"-deoxy-5-fluorocytidine (5"-DFCR) by carboxylesterase located in the liver, then to 5"-deoxy-5-fluorouridine (5"-DFUR) by cytidine deaminase highly expressed in the liver and various solid tumors, and finally to 5-FU by thymidine phosphorylase (dThdPase) preferentially located in tumor tissues. doxifluridine 122-146 cytidine deaminase Homo sapiens 160-178 10630095-3 1999 The first step is the conversion to 5"-deoxy-5-fluorocytidine (5"-DFCR) by carboxylesterase located in the liver, then to 5"-deoxy-5-fluorouridine (5"-DFUR) by cytidine deaminase highly expressed in the liver and various solid tumors, and finally to 5-FU by thymidine phosphorylase (dThdPase) preferentially located in tumor tissues. doxifluridine 148-155 cytidine deaminase Homo sapiens 160-178 10537364-8 1999 In the WiDr colon and MX-1 mammary human cancer xenograft models, the combination of a single local X-ray irradiation with either capecitabine or 5"-dFUrd was much more effective than either radiation or chemotherapy alone. doxifluridine 146-154 MX dynamin like GTPase 1 Homo sapiens 22-26 10471740-4 1999 Our previous studies identified alterations in residues which produce active TS with enhanced resistance to 5-fluorouridine (5-FdUR). doxifluridine 125-131 thymidylate synthetase Homo sapiens 77-79 10500532-0 1999 [Doxifluridine decreases serum levels of interleukin-6 in a cancer cachexia model]. doxifluridine 1-14 interleukin 6 Homo sapiens 41-54 10500532-5 1999 Oral administration of doxifluridine (5"-DFUR, 60 mg/kg or 120 mg/kg) significantly inhibited the growth of KPL-4 tumors, reduced the tissue levels of IL-6, and alleviated body weight loss. doxifluridine 23-36 interleukin 6 Homo sapiens 151-155 10500532-5 1999 Oral administration of doxifluridine (5"-DFUR, 60 mg/kg or 120 mg/kg) significantly inhibited the growth of KPL-4 tumors, reduced the tissue levels of IL-6, and alleviated body weight loss. doxifluridine 38-45 interleukin 6 Homo sapiens 151-155 10500532-6 1999 Serum IL-6 levels were also lowered by 5"-DFUR in nude mice bearing KPL-4 tumors. doxifluridine 39-46 interleukin 6 Mus musculus 6-10 10500532-8 1999 We suggest that 5"-DFUR suppresses cancer cachexia by lowering IL-6 levels in the tumor tissues and serum. doxifluridine 16-23 interleukin 6 Homo sapiens 63-67 10468288-0 1999 Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. doxifluridine 66-89 thymidine phosphorylase Homo sapiens 140-163 10468288-1 1999 5-Fluorouracil (5-FU) and 5"-deoxy-5-fluorouridine (5"-DFUR), a prodrug of 5-FU, are anticancer agents activated by thymidine phosphorylase (TP). doxifluridine 26-50 thymidine phosphorylase Homo sapiens 116-139 10468288-1 1999 5-Fluorouracil (5-FU) and 5"-deoxy-5-fluorouridine (5"-DFUR), a prodrug of 5-FU, are anticancer agents activated by thymidine phosphorylase (TP). doxifluridine 26-50 thymidine phosphorylase Homo sapiens 141-143 10468288-1 1999 5-Fluorouracil (5-FU) and 5"-deoxy-5-fluorouridine (5"-DFUR), a prodrug of 5-FU, are anticancer agents activated by thymidine phosphorylase (TP). doxifluridine 52-59 thymidine phosphorylase Homo sapiens 116-139 10468288-1 1999 5-Fluorouracil (5-FU) and 5"-deoxy-5-fluorouridine (5"-DFUR), a prodrug of 5-FU, are anticancer agents activated by thymidine phosphorylase (TP). doxifluridine 52-59 thymidine phosphorylase Homo sapiens 141-143 10468288-5 1999 The cytotoxic effects of 5-FU and 5"-DFUR were higher in TP-transfected cells as compared to wild-type cells. doxifluridine 34-41 thymidine phosphorylase Homo sapiens 57-59 11911014-3 2001 Here we report that UFT was more effective than other fluorinated pyrimidines such as 5-FU and doxifluridine (5"-DFUR) in blocking the angiogenic responses elicited by five human cancer cell lines which produced high levels of vascular endothelial growth factor (VEGF), but no detectable fibroblast growth factor-2 (FGF-2) in vitro. doxifluridine 95-108 vascular endothelial growth factor A Homo sapiens 227-261 11911014-3 2001 Here we report that UFT was more effective than other fluorinated pyrimidines such as 5-FU and doxifluridine (5"-DFUR) in blocking the angiogenic responses elicited by five human cancer cell lines which produced high levels of vascular endothelial growth factor (VEGF), but no detectable fibroblast growth factor-2 (FGF-2) in vitro. doxifluridine 95-108 vascular endothelial growth factor A Homo sapiens 263-267 11911014-3 2001 Here we report that UFT was more effective than other fluorinated pyrimidines such as 5-FU and doxifluridine (5"-DFUR) in blocking the angiogenic responses elicited by five human cancer cell lines which produced high levels of vascular endothelial growth factor (VEGF), but no detectable fibroblast growth factor-2 (FGF-2) in vitro. doxifluridine 95-108 fibroblast growth factor 2 Homo sapiens 288-314 11911014-3 2001 Here we report that UFT was more effective than other fluorinated pyrimidines such as 5-FU and doxifluridine (5"-DFUR) in blocking the angiogenic responses elicited by five human cancer cell lines which produced high levels of vascular endothelial growth factor (VEGF), but no detectable fibroblast growth factor-2 (FGF-2) in vitro. doxifluridine 95-108 fibroblast growth factor 2 Homo sapiens 316-321 10883668-3 2000 An attempt has been made to correlate the anti-cachectic activity of 5"-dFUrd with the presence of a tumour produced proteolysis-inducing factor (PIF), thought to be responsible for the development of cachexia in the MAC16 model. doxifluridine 69-77 Pif Mus musculus 117-144 10883668-3 2000 An attempt has been made to correlate the anti-cachectic activity of 5"-dFUrd with the presence of a tumour produced proteolysis-inducing factor (PIF), thought to be responsible for the development of cachexia in the MAC16 model. doxifluridine 69-77 Pif Mus musculus 146-149 10883668-7 2000 The human cervical carcinoma, Yumoto, which also induced cachexia in recipiant animals, showed expression of PIF in tumour, serum and urine in control and vehicle-treated mice, but was absent in mice treated with 5"-dFUrd. doxifluridine 213-221 dermcidin Homo sapiens 109-112 10925691-6 2000 5"-DFUR was therefore re-administrated and her CEA value declined. doxifluridine 0-7 CEA cell adhesion molecule 3 Homo sapiens 47-50 10853015-1 2000 Thymidine phosphorylase (dThdPase) is the rate-limiting enzyme that metabolizes 5"-deoxy-5-fluorouridine (5"-dFUrd, doxifluridine), an intermediate metabolite of capecitabine, to the active drug 5-fluorouracil (5-FUra), while dihydropyrimidine dehydrogenase (DPD) catabolizes 5-FUra to an inactive molecule. doxifluridine 80-104 dihydropyrimidine dehydrogenase Homo sapiens 226-257 10853015-1 2000 Thymidine phosphorylase (dThdPase) is the rate-limiting enzyme that metabolizes 5"-deoxy-5-fluorouridine (5"-dFUrd, doxifluridine), an intermediate metabolite of capecitabine, to the active drug 5-fluorouracil (5-FUra), while dihydropyrimidine dehydrogenase (DPD) catabolizes 5-FUra to an inactive molecule. doxifluridine 80-104 dihydropyrimidine dehydrogenase Homo sapiens 259-262 10853015-1 2000 Thymidine phosphorylase (dThdPase) is the rate-limiting enzyme that metabolizes 5"-deoxy-5-fluorouridine (5"-dFUrd, doxifluridine), an intermediate metabolite of capecitabine, to the active drug 5-fluorouracil (5-FUra), while dihydropyrimidine dehydrogenase (DPD) catabolizes 5-FUra to an inactive molecule. doxifluridine 106-114 dihydropyrimidine dehydrogenase Homo sapiens 226-257 10853015-1 2000 Thymidine phosphorylase (dThdPase) is the rate-limiting enzyme that metabolizes 5"-deoxy-5-fluorouridine (5"-dFUrd, doxifluridine), an intermediate metabolite of capecitabine, to the active drug 5-fluorouracil (5-FUra), while dihydropyrimidine dehydrogenase (DPD) catabolizes 5-FUra to an inactive molecule. doxifluridine 106-114 dihydropyrimidine dehydrogenase Homo sapiens 259-262 10853015-1 2000 Thymidine phosphorylase (dThdPase) is the rate-limiting enzyme that metabolizes 5"-deoxy-5-fluorouridine (5"-dFUrd, doxifluridine), an intermediate metabolite of capecitabine, to the active drug 5-fluorouracil (5-FUra), while dihydropyrimidine dehydrogenase (DPD) catabolizes 5-FUra to an inactive molecule. doxifluridine 116-129 dihydropyrimidine dehydrogenase Homo sapiens 226-257 10853015-1 2000 Thymidine phosphorylase (dThdPase) is the rate-limiting enzyme that metabolizes 5"-deoxy-5-fluorouridine (5"-dFUrd, doxifluridine), an intermediate metabolite of capecitabine, to the active drug 5-fluorouracil (5-FUra), while dihydropyrimidine dehydrogenase (DPD) catabolizes 5-FUra to an inactive molecule. doxifluridine 116-129 dihydropyrimidine dehydrogenase Homo sapiens 259-262 10530779-1 1999 5"-Deoxy-5-fluorouridine (5"-dFUrd) is a prodrug of 5-fluorouracil (5-FUra) activated by pyrimidine nucleoside phosphorylase (PyN Pase), mainly by uridine phosphorylase (Urd Pase) in rodents and by thymidine phosphorylase (TdR Pase) in humans, which is preferentially located in tumor tissues compared to normal tissues. doxifluridine 0-24 thymidine phosphorylase Homo sapiens 223-231 10530779-1 1999 5"-Deoxy-5-fluorouridine (5"-dFUrd) is a prodrug of 5-fluorouracil (5-FUra) activated by pyrimidine nucleoside phosphorylase (PyN Pase), mainly by uridine phosphorylase (Urd Pase) in rodents and by thymidine phosphorylase (TdR Pase) in humans, which is preferentially located in tumor tissues compared to normal tissues. doxifluridine 26-34 thymidine phosphorylase Homo sapiens 223-231 11810506-0 1999 Pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase indicate chemosensitivity of human colon cancer specimens to doxifluridine and 5-fluorouracil, respectively. doxifluridine 133-146 dihydropyrimidine dehydrogenase Homo sapiens 40-71 11810506-12 1999 We suggest that the activity of PyNPase and DPD represents a reliable indicator for the chemosensitivity of colon cancer to 5"-DFUR and 5-FU, respectively. doxifluridine 124-131 dihydropyrimidine dehydrogenase Homo sapiens 44-47 10410155-11 1999 These results suggest that the shrinking of tumor following 5"-DFUR therapy is closely related to TdRPase. doxifluridine 60-67 thymidine phosphorylase Homo sapiens 98-105 10097741-3 1999 Capecitabine was converted to 5"-DFUR by either human carboxyestelase or cytidine deaminase, which were mainly localized in human liver. doxifluridine 30-37 cytidine deaminase Homo sapiens 73-91 9378537-0 1997 Stimulatory effects of EGF and TGF-alpha on invasive activity and 5"-deoxy-5-fluorouridine sensitivity in uterine cervical-carcinoma SKG-IIIb cells. doxifluridine 66-90 epidermal growth factor Homo sapiens 23-26 10226570-13 1999 c) Levels of TNF-alpha and TGF-beta production in the tumor were significantly (P < 0.05) lower in the 5"-DFUR + Lentinan group compared to the control group. doxifluridine 106-113 tumor necrosis factor Rattus norvegicus 13-22 10226570-13 1999 c) Levels of TNF-alpha and TGF-beta production in the tumor were significantly (P < 0.05) lower in the 5"-DFUR + Lentinan group compared to the control group. doxifluridine 106-113 transforming growth factor, beta 1 Rattus norvegicus 27-35 9485021-2 1998 5"-dFUrd is metabolized to 5-FUra by thymidine phosphorylase (dThdPase) located in high levels in various types of solid tumors from patients, whereas 5-FUra generated is catabolized to dihydrofluorouracil by dihydropyrimidine dehydrogenase (DPD). doxifluridine 0-8 dihydropyrimidine dehydrogenase Homo sapiens 209-240 9485021-2 1998 5"-dFUrd is metabolized to 5-FUra by thymidine phosphorylase (dThdPase) located in high levels in various types of solid tumors from patients, whereas 5-FUra generated is catabolized to dihydrofluorouracil by dihydropyrimidine dehydrogenase (DPD). doxifluridine 0-8 dihydropyrimidine dehydrogenase Homo sapiens 242-245 9350241-5 1997 To assess the effect of 5"-DFUR on the activity of MMPs, we divided patients into two groups, a high and a low PyNPase activity group. doxifluridine 24-31 matrix metallopeptidase 1 Homo sapiens 51-55 10081495-5 1998 EGF and TGF-alpha up-regulated thymidine phosphorylase (dThdPase) expression of tumor cells and consequently enhanced the antiproliferative action of 5"-dFUrd, which is converted to 5-fluorouracil by dThdPase. doxifluridine 150-158 epidermal growth factor Homo sapiens 0-3 10081495-5 1998 EGF and TGF-alpha up-regulated thymidine phosphorylase (dThdPase) expression of tumor cells and consequently enhanced the antiproliferative action of 5"-dFUrd, which is converted to 5-fluorouracil by dThdPase. doxifluridine 150-158 transforming growth factor alpha Homo sapiens 8-17 10081495-8 1998 These results suggest that EGF and TGF-alpha simultaneously up-regulate the potential of ovarian adenocarcinoma cells to invade extracellular matrices and their dThdPase expression, both of which are associated with the specific action of 5"-dFUrd selectively to kill tumor cells with high invasive and metastatic potential. doxifluridine 239-247 epidermal growth factor Homo sapiens 27-30 10081495-8 1998 These results suggest that EGF and TGF-alpha simultaneously up-regulate the potential of ovarian adenocarcinoma cells to invade extracellular matrices and their dThdPase expression, both of which are associated with the specific action of 5"-dFUrd selectively to kill tumor cells with high invasive and metastatic potential. doxifluridine 239-247 transforming growth factor alpha Homo sapiens 35-44 9703363-3 1998 Among cytostatic fluorinated pyrimidines, 5"-dFUrd could inhibit the increase of NNMT activity and prevent weight loss in mice bearing clone 20. doxifluridine 42-50 nicotinamide N-methyltransferase Mus musculus 81-85 9492829-7 1998 PyNPase activities (p = 0.1668) and IAP (p = 0.0830) levels showed a decrease by 5"-DFUR administration. doxifluridine 81-88 alkaline phosphatase, intestinal Homo sapiens 36-39 9378537-0 1997 Stimulatory effects of EGF and TGF-alpha on invasive activity and 5"-deoxy-5-fluorouridine sensitivity in uterine cervical-carcinoma SKG-IIIb cells. doxifluridine 66-90 transforming growth factor alpha Homo sapiens 31-40 9378537-6 1997 These results suggest that EGF and TGF-alpha, tumor environmental factors, simultaneously up-regulate the potential of uterine cervical-carcinoma cells to invade extracellular matrices and their PyNPase activity, which are subsequently associated with the specific action of 5"-dFUrd selectively killing tumor cells of gynecological origin with high invasive and metastatic potential. doxifluridine 275-283 epidermal growth factor Homo sapiens 27-30 9378537-6 1997 These results suggest that EGF and TGF-alpha, tumor environmental factors, simultaneously up-regulate the potential of uterine cervical-carcinoma cells to invade extracellular matrices and their PyNPase activity, which are subsequently associated with the specific action of 5"-dFUrd selectively killing tumor cells of gynecological origin with high invasive and metastatic potential. doxifluridine 275-283 transforming growth factor alpha Homo sapiens 35-44 9052401-7 1997 They were more sensitive than parental PC-9 or PC9-D1 cells not only to 5"-DFUR and tegafur but also to 5-FU. doxifluridine 72-79 proprotein convertase subtilisin/kexin type 9 Homo sapiens 47-50 9279349-0 1997 [Efficacy of combination chemotherapy of cyclophosphamide and 5"-deoxy-5-fluorouridine in a mammary tumor xenograft model, MX-1]. doxifluridine 62-86 MX dynamin like GTPase 1 Homo sapiens 123-127 9279349-1 1997 Efficacy of long-term combination chemotherapy of cyclophosphamide (CPA) and 5"-deoxy-5-fluorouridine (5"-DFUR), both of which have been widely used as chemotherapeutics against breast cancer patients, was examined in a mammary tumor xenograft model, MX-1. doxifluridine 77-101 MX dynamin like GTPase 1 Homo sapiens 251-255 9279349-1 1997 Efficacy of long-term combination chemotherapy of cyclophosphamide (CPA) and 5"-deoxy-5-fluorouridine (5"-DFUR), both of which have been widely used as chemotherapeutics against breast cancer patients, was examined in a mammary tumor xenograft model, MX-1. doxifluridine 103-110 MX dynamin like GTPase 1 Homo sapiens 251-255 21590142-2 1997 PyNPase is an enzyme which converts 5"-DFUR to 5-FU in tumor tissue and has been reported to be identical to the platelet-derived endothelial cell growth factor (PD-ECGF) that has angiogenic activity. doxifluridine 36-43 thymidine phosphorylase Homo sapiens 113-160 9212806-0 1997 [Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5"-doxifluridine]. doxifluridine 167-183 thymidylate synthetase Homo sapiens 80-100 9212806-9 1997 These findings suggest that the TS inhibition rate may be an index of the anticancer effect of 5"-DFUR in colorectal cancer. doxifluridine 95-102 thymidylate synthetase Homo sapiens 32-34 9216708-1 1997 BACKGROUND: The purpose of the study was to verify whether OK-432 in combination with 5"-DFUR induced thymidine phosphorylase (TdR Pase) and cytokines in gastric cancer patients as well as in vitro. doxifluridine 86-93 thymidine phosphorylase Homo sapiens 127-135 9216708-7 1997 In the 5"-DFUR + OK-432 group, the level of IL-1 alpha production in tumor was significantly higher compared to the control group. doxifluridine 7-14 interleukin 1 alpha Homo sapiens 44-54 9216708-8 1997 In the 5"-DFUR + OK-432 group, the level of TNF alpha production in tumor was significantly higher than in normal tissue. doxifluridine 7-14 tumor necrosis factor Homo sapiens 44-53 9140116-8 1997 The results suggest that the combination therapy of 5"-DFUR plus rIL-2 enhanced non-specific cytotoxicity of LGL/NK cells for Colon 26 in tumor-bearing mice and was effective in the inhibition of tumor growth. doxifluridine 52-59 legless Mus musculus 109-112 9052401-8 1997 In addition, we demonstrated that PC9-DPE2 cells are able to potentiate the cytotoxic effects of 5"-DFUR towards co-cultured parental PC-9 cells. doxifluridine 97-104 proprotein convertase subtilisin/kexin type 9 Homo sapiens 34-37 9052401-8 1997 In addition, we demonstrated that PC9-DPE2 cells are able to potentiate the cytotoxic effects of 5"-DFUR towards co-cultured parental PC-9 cells. doxifluridine 97-104 DNA polymerase epsilon 2, accessory subunit Homo sapiens 38-42 8678502-2 1996 The titer of serum alpha-fetoprotein gradually decreased, and reduction of the hepatic tumor size was observed by abdominal computed tomography (CT) following 5"-DFUR treatment. doxifluridine 159-166 alpha fetoprotein Homo sapiens 19-36 8002395-6 1994 at 12 mg/kg/day 8 times at 3- or 4-day intervals and 5"-deoxy-5-fluorouridine (5"-DFUR) given po at 185 mg/kg/day 5 days per week for 4 weeks showed that SPM VIII had the highest effect on SC-9 human stomach cancer and COL-1 human colon cancer among the 3 compounds, resulting in a significant reduction of tumor mass. doxifluridine 53-77 cytochrome c oxidase subunit 8A Homo sapiens 158-162 21590022-2 1997 The rate of PCNA positive proliferating cells was decreased in the tretment groups, especially in AGM-1470 and in the combination of AGM-1470 and 5"-DFUR. doxifluridine 146-153 proliferating cell nuclear antigen Rattus norvegicus 12-16 8978804-0 1996 [Significance of 5"-deoxy-5-fluorouridine (5"-DFUR) administration before surgery for advanced gastric and colonic cancers--activity of pyrimidine nucleoside phosphorylase (PyNPase) and serum immunosuppressive acidic protein (IAP)]. doxifluridine 43-50 islet amyloid polypeptide Homo sapiens 226-229 8978804-9 1996 Moreover, there was significant improvement in the serum IAP level in cases with gastric and colonic cancers by pre-operative administration of 5"-DFUR. doxifluridine 144-151 islet amyloid polypeptide Homo sapiens 57-60 21597785-2 1995 Doxifluridine (5 deoxy-5-fluorouridine, dFUR) is a new fluropyrimidine derivative that demonstrated higher antitumoral activity than other fluoropyrimidines in murine tumors and optimal gastrointestinal absorption when administered orally. doxifluridine 0-13 fur Drosophila melanogaster 40-44 7759157-1 1995 5"-deoxy-5-fluorouridine (5"-FUdR) is a cytostatic that is biotransformed to 5-fluorouracil (5-FUra) by pyrimidine nucleoside phosphorylase (PyNPase), the expression of which is up-regulated by tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha) and interferon gamma (IFN gamma). doxifluridine 0-24 tumor necrosis factor Mus musculus 194-221 7759157-1 1995 5"-deoxy-5-fluorouridine (5"-FUdR) is a cytostatic that is biotransformed to 5-fluorouracil (5-FUra) by pyrimidine nucleoside phosphorylase (PyNPase), the expression of which is up-regulated by tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha) and interferon gamma (IFN gamma). doxifluridine 0-24 tumor necrosis factor Mus musculus 223-232 7759157-1 1995 5"-deoxy-5-fluorouridine (5"-FUdR) is a cytostatic that is biotransformed to 5-fluorouracil (5-FUra) by pyrimidine nucleoside phosphorylase (PyNPase), the expression of which is up-regulated by tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha) and interferon gamma (IFN gamma). doxifluridine 0-24 interleukin 1 alpha Mus musculus 235-254 7759157-1 1995 5"-deoxy-5-fluorouridine (5"-FUdR) is a cytostatic that is biotransformed to 5-fluorouracil (5-FUra) by pyrimidine nucleoside phosphorylase (PyNPase), the expression of which is up-regulated by tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha) and interferon gamma (IFN gamma). doxifluridine 0-24 interleukin 1 alpha Mus musculus 256-266 7759157-1 1995 5"-deoxy-5-fluorouridine (5"-FUdR) is a cytostatic that is biotransformed to 5-fluorouracil (5-FUra) by pyrimidine nucleoside phosphorylase (PyNPase), the expression of which is up-regulated by tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha) and interferon gamma (IFN gamma). doxifluridine 0-24 interferon gamma Mus musculus 272-299